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Summary 
Magainin 2 is a 23-residue antimicrobial peptide secreted on the skin of Xenopus laevis. In 
our study on antimicrobial peptides, this cationic, a-helical peptide and two N-terminal 
deletion analogues were synthesised. The first of the deletion peptides differed from the full 
length peptide by the omission of two amino acid residues from the N-terminus of rna gain in 2, 
while the second deletion peptide had four residues omitted from the N-terminus (termed 
magainin 2 N21 , and magainin 2 N 19 respectively). Peptides were purified by gel permeation 
chromatography and high performance liquid chromatography (HPLC). The synthetic 
peptides were of high chemical purity as verified with' electro spray ionisation mass 
spectrometry (ESI-MS) and analytical HPLC. 
To further evaluate the antimicrobial activity of the peptides in this study, a highly sensitive 
micro-gel well diffusion assay was developed. This assay was compared to a radial diffusion 
assay and a microtiter broth dilution method, using gramicidin S as model antibiotic, and 
Micrococcus lute us as the indicator organism. The micro-gel well diffusion assay was as 
sensitive as the microtiter broth dilution method, and approximately twice as sensitive as the 
radial diffusion method. Data analysis to calculate minimum inhibitory concentration (MIC), 
50% microbial growth inhibition (ICso), and maximum bactericidal concentration (MBC) was 
refined by generating dose-response curves with Prism® 2.01 (Graphpad Software Inc.). The 
MICs, determined by the three methods, were significantly different (P<O.OOI), highlighting 
the limitations involved in comparing data obtained from different methods. 
Furthermore, the synergistic antimicrobial activity of magainin 2 and tetracycline on 
tetracycline resistant Escherichia coli was investigated. The two N-terminal deletion 
analogues were also used in the synergism studies. The resistance towards tetracycline is 
caused by expulsion from resistant cells through efflux pumps. Magainin 2 was selected as 
antimicrobial peptide because of its ability to form channels in the target membrane, which 
may help in the circumvention of this form of resistance. All tests were done using the micro-
gel well diffusion assay, with the test organism being tetracycline resistant E. coli. Magainin 
2, at MIC and ICso concentrations, improved the activity of tetracycline by ±12% and ±29% 
respectively. Magainin 2 N21 improved the activity of tetracycline by ±19% at its ICso, and 
showed no effect at its MIC. Magainin 2 N 19 exhibited no antimicrobial activity on its own, 
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but still succeeded in improving the activity of tetracycline by approximately ±9% when used 
at 138 nmollmL concentration. In all three cases, this improvement was only observed at 
tetracycline concentrations below or near its MIC. At higher tetracycline concentrations the 
improvement of activity, attributed to magainin 2, was not detected. The loss in synergism 
could be the consequence of competition between tetracycline and the peptide for the 
magnesium binding sites in the lipopolysaccharide layer of the gram-negative organism. 
Intensive research is necessary to alleviate the problem of resistance, and our research 
indicates that the combination of conventional antibiotics and antimicrobial peptides in 
antibiotic preparations may be a viable option. 
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Opsomming 
Magainin 2 is 'n 23-residue peptied wat op die vel van Xenopus laevis uitgeskei word. In ons 
studies, wat handel oor antimikrobiese peptiede, is hierdie kationiese, a-heliese pep tied, sowel 
as twee N-terminaal delesie analoe gesintetiseer. Twee residue is van die N-terminaal 
weggelaat om die 21-residu delesie peptied te produseer, terwyl vier residue weggelaat is om 
die 19-residu peptied te produseer (onderskeidelik magainin 2 N21 en magainin 2 N I9 genoem). 
Peptiede is gesuiwer met behulp van gelpermeasie chromatografie en hoe doeltreffendheid 
vloeistof chromatografie (HPLC). Die hoe chemiese suiwerheid van die sintetiese produkte is 
deur elektrosproei-ionisasie massaspektrometrie (ESI-MS) en analitiese HPLC bevestig. 
Om die antimikrobiese aktiwiteit van die gesintetiseerde peptiede te evalueer was dit nodig 
om 'n hoogs sensitiewe mikro-gel dispersie essaY te ontwikkel. Hierdie essaY is met 'n radiale 
difussie- en 'n mikrotiter-mediumverdunning-essal vergelyk. Die antimikrobiese peptied, 
gramicidin S, as toetspeptied en Micrococcus luteus as die indikator organisme, is gebruik in 
die ontwikkeling van die essaY. Die mikro-gel dispersie-essal se sensitiwiteit was vergelykbaar 
met die mikrotiter-mediumverdunning-essaY, terwyl dit ongeveer twee keer so sensitief was as 
die radiale difussie-essal. Die berekening van die minimum inhibitoriese konsentrasie (MIC), 
50% inhibisie konsentrasie (ICso), en maksimum bakterisidale konsentr~sie (MBC) is verfyn 
deur die opstel van dosisrespons-kurwes met behulp van Prism®2.01 (Graphpad Software 
Inc.). Die MICs, wat in al drie metodes bereken is, het betekenisvol van mekaar verskil, wat 
aandui dat resultate van verskillende metodes nie met mekaar vergelyk kan word nie. 
Verder, is die sinergistiese antimikrobiese aktiwiteit van magainin 2 en tetrasiklien op 
tetrasiklien-weerstandbiedende Escherichia coli ondersoek. Die twee N-terminale delesie 
analoe is ook in die sinergisme studies gebruik. Die weerstandbiedendheid teenoor tetrasiklien 
word veroorsaak deur die uitpomp van die antibiotika uit die sel deur middel van 
efflukspompe. Magainin 2 is gebruik as antimikrobiese peptied omdat dit die vermoe het om 
kanale in die teikenmembraan te vorm, en moontlik hierdie vorm van weerstand kan 
verminder. AIle toetse is gedoen met behulp van die mikro-gel dispersie-essaY, waarin 
tetrasiklien-weerstandbiedende Escherichia coli as toetsorganisme gebruik is. Magainin 2, 
gebruik by MIC en ICso konsentrasies, het die aktiwiteit van tetrasiklien met ±12% en ±29% 
onderskeidelik verbeter. Magainin 2 N21 by ICso, het die aktiwiteit van tetrasiklien met ±19% 
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verbeter, maar het geen effek by sy MIC getoon. Magainin 2 N I9 het geen antimikrobiese 
aktiwiteit getoon nie, maar het weI die aktiwiteit van tetrasiklien met ±9% verbeter as dit by 
138 nmol/mL gebruik word. In al drie gevalle is sinergisme net gevind by konsentrasies laer 
of naby die MIC van tetrasiklien. By hoer tetrasiklienkonsentrasies het die verbetering in 
aktiwiteit, as gevolg van die teenwoordigheid van magainin 2, verlore gegaan. Die verlies in 
sinergisme is moontlik as gevolg van kompetisie tussen tetrasikIien en magainin 2 vir 
magnesiumbindingplekke op die IipopoIisakkariedIaag van Gram-negatiewe organismes. Baie 
navorsing moet egter nog gedoen word om die probleem van weerstand teen antibiotika te 
oorkom. Hierdie resuitate bewys dat die kombinasie van konvensionele antibiotika en 
antimikrobiese peptiede weI weerstand kan verminder. 
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Preface 
When penicillin became available during the second world war, it was a medical miracle, 
rapidly vanquishing the biggest wartime killer, namely infected wounds. Discovered initially 
by a French medical student, Ernest Duchesne, in 1896, and then rediscovered by Scottish 
physician Alexander Fleming in 1928, the product of the soil mold Penicillium crippled many 
types of disease-causing bacteria. However, only four years later after drug companies began 
mass-producing penicillin in 1943, microbes began appearing that could resist it. Medical 
researchers subsequently fought back with the development of novel analogues such as 
methicillin and oxacillin. By 1953, the antibiotic armamentarium included chloramphenicol, 
neomycin, terramycin, tetracycline, and cephalosporins. Today, however, it is feared that we 
are nearing an end to the seemingly endless flow of antimicrobial drugs. Emergence of forms 
of Staphylococcus aureus lacking sensitivity to vancomycin signifies that organisms 
untreatable by every known antibiotic are on their way. All hope is not, however, lost. In the 
past 50 years researchers have discovered that the innate immunity in various 
microorganisms, plants, amphibians, and insects is mediated through the presence of small 
molecular weight antimicrobial peptides. In the past, researchers have concentrated mainly on 
the discovery and isolation of these peptides, and it is only recently that their potential as 
future antibiotics is being recognised. 
This thesis describes how the unique mechanism of action of one such peptide, magainin 2, is 
exploited to alter the membrane viability of resistant organisms and make them more 
susceptible to the action of conventional antibiotics. In Chapter 1 a brief overview on 
resistance and the antimicrobial peptide magainin is given. In the following three chapters, the 
experimental results obtained in this study are reported. In Chapter 2, the synthesis, 
characterisation, and purification of magainin 2 and two N-terminal deletion analogues are 
discussed. Chapter 3 describes the development and evaluation of an antimicrobial assay used 
to test the antimicrobial activities of these peptides. In Chapter 4 we report on the ability of 
these peptides to make resistant organisms more susceptible to conventional antibiotics. 
Finally, the general implications and future prospects of this work are discussed in Chapter 5. 
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Chapter 1 
General Introduction 
1.1 The problem of antibiotic resistance 
To date, antibiotics have been highly successful in treating varIOUS infectious diseases. 
However, the emergence of numerous strains of resistant bacteria has rapidly changed this 
situation. The mortality rate in major hospitals, staffed by highly competent personnel, has 
risen alarmingly as a result of infections by resistant bacteria [1]. Bacterial resistance is not a 
recent problem, with penicillin resistant Staphylococcus aureus having been discovered as far 
back as the 1950s. The frequency of antibiotic resistant bacteria has increased to such an 
extent that certain strains have developed resistance to multiple drugs, with some bacteria 
being resistant to 8-10 antibiotic agents. Up until now, pharmaceutical companies have kept 
this problem from reaching epic proportions by constantly developing alternative or new 
antibiotics [2]. Today there are more than 50 penicillins, 75 cephalosporins, 12 tetracyclines, 
nine aminoglycosides, three carbapenems, and at least 20 fluoroquinolones [3]. The result has 
been a steady supply of new antibiotics to keep ahead of the problem. The development of 
new antibiotics, however, has slowed dramatically, with no new antibiotic groups foreseen in 
the next 10 years [4]. Of major concern is the development of vancomycin resistant S. aureus, 
signifying the emergence of bacteria resistant to every known antibiotic [5]. 
Increased antibiotic resistance has also had enormous cost implications for health care. These 
result from the use of more costly antibiotics, the need for additional drug testing, prolonged 
hospital stays, and difficulty in eradicating resistant bacteria. While the health systems of 
developed countries may be able to cover the additional costs associated with antibiotic 
resistance, those of developing countries are not. With the lack of cheap alternatives, 
developing countries are likely to continue to misuse antibiotics and therefore further 
compound the problem of resistance. 
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With the unsure future of antibiotics and the rising health care costs associated with the 
increase in antibiotic resistance, researchers are constantly searching for ways and means to 
reduce or overcome bacterial resistance. Pharmaceutically, either more effective antibiotics 
must be developed, or agents based on the mechanism of resistance must be identified and 
utilised. 
The rest of this chapter shall review the following aspects: first, the various pathways by 
which resistance spreads, and mechanisms used by bacteria to incur resistance; second, 
antimicrobial peptides from the animal kingdom, specifically the frog peptide magainin and 
how its antimicrobial characteristics and unique mechanism of action make it ideal for use in 
future research. 
1.2 Resistance pathways 
It is suspected that there are at least six pathways involved in the appearance or spread of 
resistance in bacteria [6], which will be discussed separately below. 
1.2.1 Introduction of resistant organisms into a previously susceptible 
population 
Often resistant organisms are able to spread or find their way to new or "unaffected" areas. 
For example, new strains can enter the hospital setting by way of a patient from the outside, a 
health-care worker from the outside or another institution, or a contaminated commercial 
product. This has been illustrated by an episode in which a strain of Burkholderia cepacia was 
introduced into a hospital setting by means of a contaminated iodophor solution which caused 
only those patients who were treated with the solution to be affected [6]. Research shows that 
the introduction of resistant strains into hospitals from nursing homes and extended care 
facilities, as well as transfer in the opposite direction from hospital to nursing home, has 
become common for certain pathogens [7]. Once resistant strains find their way into various 
institutions they are extremely difficult to eliminate. Furthermore, the transfer of resistant 
organisms from the medical environment to the community is also a common occurrence. 
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1.2.2 Genetic mutation 
Changes in only a few base pairs, causing the substitution of one or a few amino acids in a 
crucial target (enzyme, cell structure, or cell wall) can affect chromosomal structure or control 
genes leading to new resistant strains [8]. An example of this is shown by certain strains of 
Escherichia coli which have developed resistance to quinolones [9]. Normally, quinolones 
antagonise bacteria by inhibiting DNA gyrase, an essential bacterial enzyme with A and B 
subunits. Certain strains of E. coli have developed resistance to quinolones by altering the 
gyrase target site in either the A or B subunit. These changes have resulted in the inactivation 
of numerous antibiotics that were previously able to control these organisms. Hospitalised 
patients treated with antibiotics prone to select altered resistance traits can quickly become 
infected with these resistant strains. 
1.2.3 Transfer of genetic material 
It is also possible that resistance can be acquired by a previously susceptible strain from 
another species or genus [10]. It has been shown that many of the antibacterial resistance 
genes are found on plasmids that can transfer themselves from one genus or species of 
bacteria to another [11]. Although the ability of microorganisms to exchange genetic material 
is a known fact, it is evident that researchers have underestimated the extent of this DNA 
exchange network. There is even evidence to date of the exchange of genetic information 
between Gram-negative and Gram-positive organisms, although the frequency of such events 
is unknown [12]. Of particular interest, and concern, is the exchange pathway between 
staphylococci and enterococci. Already, the genes encoding f3-lactamase production and 
high-level gentamicin resistance have moved from staphylococci into enterococci. This has 
resulted in resistance to penicillin, ampicillin, and the aminoglycosides [6]. In 1988, it was 
discovered that Enterococcus faecalis was resistant to vancomycin by virtue of a gene (van A) 
carried on a transmissible plasmid [9]. Back then it was thought that the plasmid encoding 
vancomycin resistance could only be transferred to other streptococci; alarmingly though 
certain strains of vancomycin resistant S. aureus have recently been discovered [5]. 
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1.2.4 Emergence of strains with inducible resistance 
Chromosomal determinants for resistance to a given drug may not be expressed until the 
organism comes into contact with that drug or similar compounds [6]. When permissive 
conditions appear, for example the use of new antibiotics or the introduction of new 
conjugative plasmids, resistance can be manifested rapidly. The trigger for this resistance 
could be the antimicrobial agent to which the resistance is directed. In some cases, exposure to 
another antimicrobial agent results in induction or depression of a determinant, such as an 
enzyme etc., that stimulates resistance to that specific antimicrobial agent. 
1.2.5 Selection of resistant strains 
When using a specific antibiotic to kill a certain microorganism the majority of the population 
is successfully killed; however, often a resistant subset of the strain remains unaffected [6]. 
Frequently a minority of strains present in a given population may be resistant to a specific 
antibiotic used, therefore making the antibiotic the selecting factor [13]. It is also found that 
non-drug factors, such as those causing acetylation or glucuronylation, can change certain 
strains, thus inadvertently resulting in a selection process. 
1.2.6 Circulation of resistant strains 
Resistant strains have been shown to spread in a variety of ways within the health-care setting. 
For example, organisms can spread from patient to patient, from one patient to another via a 
health-care worker, in contaminated commercial products (for example antiseptics), or 
widespread transfer of genetic material from the original organism to others [6]. 
1.3 Why does resistance develop? 
The most current outbreaks of resistance involve a number of the above mentioned pathways, 
each contributing to a greater or lesser degree. For example, in a previous case where a 
hospital outbreak of multiresistant Serratia marcescens took place, it was discovered that the 
outbreak occurred via transmission on the hands of health-care workers who handled 
contaminated collection basins while emptying the urine catheter collection bags [6]. Two 
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pathways played a role in this outbreak: the first was the introduction of a new organism into 
the hospital environment, and the second was the transfer of this organism within the hospital. 
These pathways, acting alone or in tandem with one another, therefore resulted in the rapid 
spread of resistant organisms. It is seldom possible to identify which of the pathways was 
operative in a given abrupt increase in resistance, which implies that the magnitude of each 
outbreak of resistance in today's settings still remains unclear. Three basic aspects need to be 
studied in detail if the spread of resistant organisms is to be curbed. First, simple mutations in 
genes which produce target proteins. Second, the exchange of genetic material among micro-
organisms which results in them becoming resistant to additional antibiotics. Finally, how the 
use of large quantities of antibiotics, not just within the hospital environment, but also in 
community, farm, and aquaculture settings, has increased the selection of new resistant 
organisms [6]. 
1.4 Mechanisms of antibiotic resistance 
Bacteria are known to utilise several mechanisms to develop antibiotic resistance. These 
mechanisms can either be specific or general in their mode of action. Specific mechanisms 
include degradation of the drug, inactivation of the drug by enzymatic modification, and 
alteration of the drug target. The more general mechanisms include cases where, for example, 
an organism can surround itself with a barrier of low permeability or expel the drug by means 
of an energy dependent pump [1]. The focus here will be on the general mechanisms of 
resistance. 
1.4.1 Bacterial species surrounded by low-permeability barriers 
Bacteria are unicellular organisms and their cytoplasm is separated from the external 
environment by the cytoplasmic membrane. The major permeability barrier in any membrane 
is the lipid bilayer structure, and its barrier property is inversely correlated with its fluidity 
[1]. It is impossible to make the cytoplasmic membrane much less permeable, because this 
would require decreasing the membrane fluidity and consequently interfering with the proper 
functioning of membrane proteins. Therefore some bacteria protect themselves by 
constructing an additional structure that surrounds the cell outside the cytoplasmic membrane. 
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Most Gram-positive bacteria are surrounded by a thick peptidoglycan cell wall (Fig. 1.1). This 
structure, although mechanically strong, appears to offer little resistance to the diffusion of 
small molecules such as antibiotics. In contrast, Gram-negative bacteria, such as E. coli, 
surround themselves with a second membrane, which functions as an effective barrier. This 
membrane IS composed of lipopolysaccharide (LPS), rather than the usual 
glycerophospholipid found in most other biological membranes. The fatty acid chains present 
in LPS are all saturated, which creates a much more tightly packed membrane with a greatly 
decreased fluidity (Fig. 1.1) [14]. In addition, a LPS molecule contains six or seven covalently 
linked fatty acid chains, in contrast to the glycerophospholipid that contains two fatty acid 
residues. The vast majority of clinically important antibiotics do have some hydrophobic 
properties and can therefore diffuse across the LPS leaflet. The rate at which this occurs 
though is very slow, indicating that the LPS leaflet does serve as an efficient barrier against 
the rapid penetration of antibiotics into the cell. Bacteria surrounded by such an effective 
barrier, however, must develop a separate mechanism to take up essential nutrients from the 
external medium. For this purpose, the outer membrane contains proteins of a special class, 
porins, which produce non-specific aqueous diffusion channels across the membrane. It is 
through these channels that relatively hydrophilic antibiotics can penetrate the cell. A different 
strategy is adopted by the Gram-negative soil organism, Pseudomonas aeruginosa. This 
organism does not possess the classical high-permeability porins, but instead contains only 
low-efficiency porins that allow diffusion of small molecules at one-hundredth the rate of the 
classical porin channels [15]. Thus, hydrophilic antibiotics diffuse across the outer membrane 
at a very slow rate making this organism resistant to a wide variety of antibiotics. Certain 
Gram-positive mycobacteria have adopted a similar strategy of surrounding themselves with a 
barrier of generally low permeability. The mycobacterial barrier appears to consist of a lipid 
bilayer of unusually high order, and therefore low fluidity, making the mycobacterium 
resistant to a broad spectrum of antibiotics [16]. 
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Figure 1.1. Cell envelopes of bacteria [1]. Most of the Gram-positive bacteria are covered 
by a porous peptidoglycan layer, which does not exclude most antimicrobial 
agents (left). Gram-negative bacteria are surrounded by the outer membrane, 
which functions as an efficient permeability barrier because it contains LPS and 
porins with narrow, restrictive channels (middle). Mycobacteria produce an 
unusual bilayer, which functions as an exceptionally efficient barrier, outside the 
peptidoglycan layer (right) [1]. 
The main fatty acid in the mycobacterial cell wall is mycolic acid, which contains 70 carbon 
atoms with only a few double bonds, making its fluidity extremely low (Fig. 1.1). In LPS, six 
or seven fatty acids were joined to a single head group; here, hundreds of mycolic acid 
residues are covalently linked to a common head group, an arabinogalactan polysaccharide, 
which in turn is covalently linked to the underlying peptidoglycan structure [17]. The influx 
of nutrients is apparently facilitated by the mycobacterial porin, which is present in very small 
amounts and allows only very slow diffusion of small molecules through its channel [1]. The 
low permeability of both the lipid matrix and of the porin channel results in the very slow 
penetration by antibiotics. 
Experimentally, it has been shown that reduced permeability of the outer membrane alone 
does not provide complete resistance to antibiotics, and that significant levels of drug 
resistance requires a second contributor. This second contributor can have a direct specific 
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effect on the drug itself (degradation of the drug or enzymatic inactivation of the drug), or it 
can constitute a general, active efflux of the drug. 
1.4.2 Active efflux as a mechanism of drug resistance 
Active drug efflux systems in bacteria can be divided into four families (Table 1.1) on the 
basis ofsupramolecular assembly, mechanism, and sequence homology: 
1. the "major facilitator (MF) family", which shows sequence homology to the glucose 
facilitators of mammalian cells and includes drug efflux proteins of eukaryotic microbes; 
2. the resistance-nodulation-division (RND) family, which also includes transporters that 
pump out cadmium, cobalt and nickel ions; 
3. the staphylococcal multidrug resistance (Srnr) family, consisting of small transporters that 
presumably contain only four transmembrane helices; and 
4. the ATP-binding cassette (ABC) transporters, which are composed of two transmembrane 
and two ATP-binding domains [1]. 
Each member of the first three families is a single cytoplasmic membrane protein that expels 
drugs using the proton-motive force, or in other words acting as a H+-drug antiporter [1]. Of 
great concern today is the discovery of multidrug efflux systems, confirming the general 
mechanism of resistance that certain organisms have acquired. Efflux systems such as QacA, 
Srnr, QacE, or MvrC are able to pump out quaternary amine compounds as well as basic dyes 
[1]. This indicates that the substrates of these systems are at least physically similar, being 
amphiphilic with positive charges. In contrast, the Bmr transporter, found in a rhodamine-6G-
resistant mutant of Bacillus subtilis, catalysed the active efflux not only of cationic dyes such 
as rhodamine-6G and ethidium bromide, antibiotics puromycin (basic) and netropsin (strongly 
basic), and an organic cation, tetraphenylphosphonium, but also chloramphenicol (uncharged) 
[1]. 
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Table 1.1. Examples of active efflux systems in bacteria (1]. 
Transporter Organism Accessory protein Gene location 
Major facilitator in Gram-positives 
OtrB Streptomyces r;lIIo.\'Wi None Chromosome 
Tel (L) Various cocci, Bacillus .vuhtilis None Plasmid 
Mmr S'treplolllyce,\' coe/ic%r None Chromosome 
Act II Streptomyces coelic%r None Chromosome 
TcmA Streptomyces glaucescells None Chromosome 
NorA ."'llphy/oc(}CCIiS aurelts None Chromosomal 
QacA Staphylococcus allrel/S None Plasmid 
Bmr Bacillus suhtili.,· None Chromosome 
Major facilitator in Gram-negatives 
TelA Escherichia coli None Plasmid 
CmlA Pseudomonas aenJginosll None Plasmid 
Bcr Escherichia. coli None Chromosome 
EmrB Escherichia. coli EmrA Chromosome 
EmrD Escherichia. coli ? Chromosome 
RNDfamily 
AcrE(AcrB) Escherichia. coli AcrA Chromosome 
EnvD E,·cherichia. coli EnvC Chromosome 
MexB Pseudomonas aeruginosa MexA Chromosome 
Smr(QacC) Staphylococcus llureliS None Plasmid 
QacE Klebsiella aero genes Plasmid 
MvrC(EmrE) Chromosome 
ABC transporters 
MsrA Staphylococcus epidermidis ? Plasmid 
DITA,DITB S"reptomyce,\' pel/eeliu.\' Chromosome 
TIrC, TIrB Streptomyces fradiae Chromosome 
Substrate 
Oxytetracycline 
Tetracycline 
Methylenomycin 
Actinorhodin 
Tetracenomycin 
Fluoroquinolones, basic dyes, 
puromycin, chloramphenicol, 
tetraphenylphosphonium 
Quaternary ammonium 
compounds, basic dyes 
Basic dyes, chloramphenicol, 
puromycin, fluoroquinolones 
Tetracycline 
Chloramphenicol 
Bicyclomycin 
CCCP, nalidixic acid, 
tetrachlorosalicylanilide, 
phenyl mercury acetate 
CCCP, phenylmercury acetate 
Basic dyes, SDS, erythromycin, 
novobiocin, fusidic acid, 
tetracycline, phenyl mercury acetate 
Basic dyes, SDS, erythromycin, 
fusidic acid, tetracycline, 
mitomycin c 
Tetracycline, chloramphenicol, 
fluoroquinolones, J3-lactams, 
pyoverdine 
Quaternary ammonium 
compounds, basic dyes 
Quaternary ammonium 
compounds, basic dyes 
Methyltriphenylphosphonium, 
basic dyes 
14- and 15-membered macrolides 
Daunorubicin, doxoribucin 
Tylosin 
Note: QacB is very similar to QacA; CCCP, carbonyl cyanide m-chlorophenylhydrazone; SOS, sodium dodecylsulfate 
1.9 
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1.4.3 The efflux system and the outer membrane barrier 
Efflux transporters are located in the cytoplasmic membrane, and therefore in Gram-negative 
cells it may be assumed that antibiotics are pumped out into the periplasm (Fig. 1.1). If this is 
indeed the case, the efflux is unlikely to make these bacteria more resistant, because the 
antibiotic will in all likelihood be unable to leave the cell easily because of the outer 
membrane barrier. 
OM channel 
Accessory protein ---
Efflux transporter 
n Amphiphilic 
'I' drug 
Outer 
membrane 
Cytoplasmic 
membrane 
Figure 1.2 Proposed structure and mechanism of action of most efflux complexes in 
Gram-negative bacteria [1]. The efflux transporter is usually of the MF or RND 
family. This is connected to the accessory protein, such as ErnrA, AcrA, EnvC 
or MexA, which in turn is associated with an outer membrane channel protein, 
OprK in the MexAB system of P. aeruginosa and probably TolC in E. coli. 
Amphiphilic drugs (with their hydrophilic ends shown as black rectangles) 
traverse the outer membrane (often via porin channels), and become partially 
inserted into the bilayer of the cytoplasmic membrane. The transporter captures 
the drug molecules in the bilayer and pumps them out, bypassing the outer 
membrane barrier [1]. 
One way to overcome this barrier was suggested by the presence of accessory proteins that 
occur together with many efflux transporters of both MF and RND families in Gram-negative 
cells (Table 1.1). These proteins are thought to bridge the cytoplasmic transporter and an outer 
membrane channel, so that the drugs can be pumped directly into the surrounding medium 
rather than the periplasm (Fig. 1.2). As mentioned, the low permeability of the outer 
membrane is unlikely to produce clinically significant levels of resistance, and a second 
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contributor is needed for this purpose. In many systems, the active efflux system appears to be 
this second factor. This, however, does not mean that the outer membrane barrier is 
unimportant. Since the intracellular concentration of any drug is the result of a balance 
between influx and efflux, it is likely that the slow influx of various agents through the low 
permeability outer membrane makes efflux an especially effective mechanism for resistance 
in many bacteria. 
1.5 Alternative antimicrobial agents 
Plants and animals have to survive in a world laden with pathogenic bacteria and fungi. 
Perhaps the most interesting aspect of this ecosystem is not the expected staggering losses 
from susceptibility to infection, as much as the endurance displayed by the diverse organisms 
in spite of infection [18]. This resilience may be attributed to the presence of a repertoire of 
host defence mechanisms. In animals (including humans), defence may be mediated by events 
such as immune response, complement activation, phagocytosis, and release of small 
molecular weight antimicrobial peptides [19]. However, in insects, amphibians, and other 
lower organisms--although comparable immune responses are less well charecterised-it is 
clear that small molecular weight peptides playa major role in warding off infections [20]. 
From the perspective of a microbe, the tissues of living multicellular organisms are rich 
sources of nutrients. Challenged by the remarkable plasticity of such microbes, vertebrates 
have evolved multiple and varied molecular defences. Amongst these defences are an array of 
constitutive or inducible antimicrobial proteins or peptides [21]. Examples of vertebrate 
antimicrobial peptides include defensins and cathelicidins, both of which exhibit 
broad-spectrum activity [22]. A host of antimicrobial peptides have also been discovered in 
plants and insects [23]. The plant defensin family includes the cysteine-rich u- and p-thionins 
[24]. Of the insect peptides, the most well studied examples are the cecropins and melittin. 
Cecropins are a family of homologous antibacterial peptides derived from the Cecropia moth, 
Hyalophora cecropia [25]. Cecropin-like peptides have also been found in lepidoptera 
(butterflies and moths), diptera (flies etc.), and the porcine intestine and blood cells of marine 
protochordate [26]. Melittin is another insect peptide comprised of 26 amino acid residues, 
and is isolated from the venom of honeybees [27]. Many more peptides have been isolated 
from insects such as fruit flies, silkworms, etc. [18, 22, 23]. Certain bacteria are also known 
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secrete various antimicrobial peptides. Because bacteria are prolific, they continually interact, 
with almost all other cell types. Therefore, many non-bacterial cells, as well as many bacteria, 
produce specific antimicrobial peptides to combat a bacterial "take-over" of their environment 
[28]. Bacterial peptides produced by non-ribosomal biosynthesis include gramicidin S from 
Bacillus brevis, and alamethicin from the fungus, Trichoderma viride. As opposed to these 
peptides, the group of peptides termed bacteriocins are produced on the ribosome as a 
precursor peptide, which is later processed to release the active moiety [29]. Bacteriocins can 
be divided into several classes: class I are the lantibiotics, which are small membrane active 
peptides containing post-translationally modified lanthionine residues, while class II-IV are 
the non-Iantibiotics which contain no lanthionine residues (subdivisions to class II 
bacteriocins have also been suggested) [30, 31]. These, together with numerous other 
peptides, have been reviewed extensively elsewhere [18, 22, 23, 28]. 
Perhaps the richest source of antimicrobial peptides is frog skins. The abundance of peptides 
varies between species; particularly rich sources have been discovered within the genera 
Phylomedusa and Xenopus. Peptides secreted by Xenopus laevis are produced in the granular 
glands, which are made up of numerous specialised secretory cells that store large amounts of 
biologically active peptides and neurotransmitters. These glands are believed to serve 
physiological roles in defence against macroscopic predators, and in microbial control 
following wounding. Isolation of cDNAs encoding these peptides has revealed that they are 
initially synthesised as large polyproteins in the secretory cells. The precursors share a highly 
conserved signal sequence, approximately 20 amino acids in length, with several clusters of 
sequence identity and an overall amino acid identity of about 55% [32]. Prior to secretion, 
proteolytic events cleave the precursor peptides, liberating the active peptide fragments [31]. 
Peptides secreted by Xenopus laevis include caerulein precursor fragments, xenopsin 
precursor fragments, PGLa, and magainin land 2 [32]. Experimental determination of protein 
yield showed the magainin peptides to be the major component of the exudate [33]. Following 
discharge, the peptides undergo proteolytic cleavage at the N-terminal side of a lysine residue 
(at Xaa-Lys bonds where Xaa is Leu, Gly, Ala or Lys) by the action of an endopeptidase, 
resulting in half peptides that no longer retain antibiotic activity [34]. This may represent a 
mechanism by which the secretions are rendered harmless to the frog itself, since prolonged 
exposure could possibly result in toxic effects [35]. 
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The magainin pep tides exhibit antimicrobial activity against a wide range of target organisms 
including protozoa, fungi, Gram-positive and Gram-negative bacteria, and certain cancer cell 
lines [36]. They were also noted to be both non-hemolytic and non-cytotoxic [37]. Unique 
structural features of these peptides are their cationic nature and amphipathic ex-helical 
conformation on membrane binding (Fig. 1.3) [38]. The above mentioned characteristics 
indicate that these peptides have excellent potential as antibiotics, and with the steady decline 
in effective conventional antibiotics, antimicrobial peptides could well be the antibiotics of 
the future. Magainin 2, possessing a broad-spectrum of activity and being non-cytotoxic, is 
also one of the most well documented antimicrobial pep tides making it ideal for future 
research. In the following, the characteristics of the peptide, its mechanism of action, and 
research showing its overall versatility as antimicrobial compound will be discussed. 
Figure 1.3 Helical wheel projection ofmagainin 2. Polar residues are boxed [39]. 
1.6 The antimicrobial peptide magainin 
1. 6.1 General characteristics of the magainins and their analogues 
As stated previously, a number of magainins have been isolated from the dermal secretions of 
Xenopus laevis. These have led to the development of numerous other synthetic magainin 
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analogues with increased antimicrobial activity. Both the natural and synthetic peptides were 
indistinguishable with respect to both biological and chromatographic properties [36]. Some 
of these magainins together with their amino acid sequences are listed in Table 1.2. 
Table 1.2 Amino acid sequences of magainin and its analogues. Magainin 1 and 2 are the 
only naturally occurring peptides [40] . 
Peptide Sequence 
Magainin 1 G I G K F L H S AGKF GKAF V G E I M K S 
Magainin 2 G I G K F L H S AKKF GKA F VGE I M N S 
Magainin A ~A I GKF L HA AKKF AKA F V A E I M N S 
Magainin B A I G K F L HA AKKF AKA F V A E I M N S 
Magainin C N-Acetyl A I GKF L HAAKKF AKAF VAE I M N S 
MagaininD ~AG I GKF L H S AKKF AKAF VAE I M N S 
Magainin E ~A I G K F L H S AKKF AKAF V A E I M N S 
Magainin F G I G K F L H S AKKF AKA F VA E I M N S 
Magainin G ~AG I GKF L H S AKKF AKA F VAE I M N S 
Magainin H G I GKF L H S a K K F a K A F V a E I M N S 
Note: All sequence modifications are based on magainin 2. One-letter ammo acid 
abbreviations are used. ~A, ~-alanine; a, D-alanine. 
1.6.2 Antimicrobial and haemolytic activity 
Table 1.3 lists the antimicrobial activities of the magainin peptides and their analogues after 
being assayed against Gram-positive and Gram-negative bacteria. Analogues A, B, D, E, F, 
and G had increased antimicrobial activity, between one and two orders of magnitude higher 
than magainin 1 or 2, while still maintaining the same spectrum of activity [40]. The H 
analogue, which contains D-alanine instead of L-alanine at three modification sites, showed 
no signs of increased antimicrobial activity against any of the microorganisms tested, 
indicating that a specific conformation was required for antimicrobial activity. To determine 
NH2 
NH2 
NH2 
NH2 
NH2 
NH2 
NH2 
NH2 
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the haemolytic activity of magainin 1 and analogues A, B, C, F, G, and H, experiments were 
performed using human erythrocytes. The control peptide used to denote 100% haemolysis 
was honey bee venom, or melittin. Neither magainin 1 nor analogue H showed haemolytic 
activity at 250 ~g/ml of heparinised blood. However, the other analogues exhibited 
appreciable haemolysis at 100 ~g/ml which was approximately equivalent to 11100 of the 
potency of melittin [40]. Analogue G showed less than 1 % haemolytic activity at 200 ~g/ml. 
These results indicate that the haemolytic activities generally increased in parallel to growth 
inhibitory activity, except in the case of analogue G, which showed high antimicrobial activity 
but exceptionally low haemolytic activity [40]. 
Table 1.3 Antimicrobial activity of magainin and its analogues [40] . 
Organism 50% and 100% minimal inhibitory concentrations (llg/mL) 
Magainins Analogues 
1 2 A B C D E F G H 
Escherichia coli 100 50 1.2 1.2 10 2.5 1.2 1.2 2.5 70 
250 100 2.5 2.5 25 5 5 5 5 >100 
Klebsiella pneumoniae 100 100 5 5 60 10 5 5 10 100 
250 100 25 10 100 25 25 25 25 >100 
Pseudamonas aeruginosa 430 >100 15 15 >100 25 25 25 25 100 
>500 >100 25 25 >100 50 50 50 100 >100 
Streptococcus agalactiae 60 50 0.25 0.25 0.5 0.25 0.25 0.25 0.5 100 
75 100 1 1 1 1 1 1 2.5 >100 
Streptococcus faecalis 360 >100 5 5 5 5 10 10 10 >100 
>500 >100 10 10 25 25 25 25 50 >100 
Staphylococcus aureus 500 >100 5 5 7.5 2.5 5 5 5 >100 
~-lactamase [+] >500 >100 10 10 2.5 5 10 10 10 >100 
Staphylococcus aureus 360 >100 5 5 10 10 10 10 10 >100 
~-Iactamase [-] >500 >100 10 10 25 25 25 25 25 >100 
Note: > denotes no activity detected at the concentration indicated. 
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1.6.3 Proposed models for the mechanism of action of linear amphipathic 
a-helical peptides 
Although the exact mechanism of action of these peptides is still not clearly understood, 
membrane permeation by amphipathic a-helical peptides has been proposed to proceed via 
one of two mechanisms: (a) transmembrane pore formation via a "barrel-stave" mechanism, 
or (b) membrane destructionlsolubilisation via a "carpet-like" mechanism [41]. 
1.6.3.1 Model of membrane disruption by "barrel-stave" transmembrane pore 
formation 
A classical transmembrane pore can be described by a barrel-stave model in which 
transmembrane amphipathic a-helices form bundles, with their hydrophobic surfaces 
interacting with the lipid core of the membrane, and their hydrophilic surfaces pointing 
inwards producing a pore (right panel Fig. 1.4) [42]. As these peptides can insert into the 
hydrophobic core of the membrane, their binding to the target membrane is predominantly 
driven by hydrophobic interaction. As a consequence, 'they can bind to both zwitterionic and 
charged phospholipid membranes. Furthermore, because the hydrophobic surfaces' of several 
amphipathic a-helical peptides are facing each other while forming a transmembrane pore, it 
is unlikely that such helices will be highly homogeneously charged. The barrel-stave 
mechanism involves four major steps: (a) binding of the monomers to the membrane in an 
a-helical structure, (b) molecular recognition between membrane-bound monomers that leads 
to their assembly already at low surface density of bound peptide, (c) insertion of at least two 
assembled monomers into the membrane to initiate the formation of a pore, and (d) 
progressive recruitment of additional monomers to increase the pore size. A prerequisite 
condition for such a mechanism is that initial assembly of monomers on the surface of the 
membrane must occur before the peptide is inserted [41]. It is energetically unfavourable for a 
single amphipathic a-helix to traverse the membrane as a monomer owing to the fact that the 
low dielectric constant and inability to establish hydrogen bonds will not allow the fatty acyl 
region of a lipid bilayer to be in a direct contact with a polar surface of a single amphipathic 
a-helix [41]. 
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1.6.3.2 Model of membrane disruption via a "carpet-like" mechanism 
The carpet mechanism describes a situation in which amphipathic a-helical peptides initially 
bind onto the surface of the target membrane and cover it in a carpet-like manner [43, 44]. 
The target membrane can be permeated only after a threshold concentration has been reached. 
In contrast to the barrel-stave mechanism, the peptide does not insert into the hydrophobic 
core of the membrane, but rather binds to the phospholipid headgroups. Initial interaction with 
the negatively charged target membrane is electrostatically driven, and therefore the active 
peptides are positively charged. The four steps possibly involved in this model are (a) 
preferential binding of positively charged peptide monomers to the negatively charged 
phospholipids, (b) laying of amphipathic a-helical monomers on the surface of the membrane 
so that the positive charges of the basic amino acid residues interact with the negatively 
charged phospholipid headgroups or water molecules, (c) rotation of the molecule leading to 
reorientation of the hydrophobic residues toward the hydrophobic core of the membrane, and 
(d) disintegration of the membrane by disrupting the bilayer curvature leading to 
micellisation. An initial step before the collapse of the membrane packing may include 
transient holes in the membrane. Transient holes allow the non-specific influx of various ions 
into the cell, and therefore should also have a cytostatic, or even cytotoxic effect on the cell, . 
owing to disruption of the membrane potential. Transient holes are explained by the toroidal 
(or wormhole) model [45,46]: initial adsorption of the peptides to the headgroups expands the 
membrane laterally, consequently decreasing the bilayer thickness in proportion to the peptide 
concentration. Because the energy of membrane deformation is proportional to the square of 
the thickness change, the energy increases quadratically with the peptide concentration. The 
energy of membrane deformation is part of the free energy of peptide adsorption. Thus at high 
peptide concentrations, the energy of adsorption may become so high that it drives the 
lipid-peptide system to configurations of lower energy, causing the membrane to fold back on 
itself like the inside of a torus (step B in left panel of Fig. 1.4). The strain of membrane 
expansion is reduced by the incorporation of peptide monomers in the headgroup region, thus 
stabilising the transient holes. These holes may also allow for the passage of peptide 
molecules from the outer membrane into the inner membrane of, for example Gram-negative 
bacteria, in a process referred to as "self-promoting uptake" [47]. 
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"carpet" mechanism ~ ~ .... / "barrel-stave" mechanism 
..------- ~ ---------.... 
Figure 1.4 In the carpet-like model (left panel) cationic peptides bind the negatively 
charged phospholipid headgroups of the membrane and form an a-helix (step 
A). When a threshold concentration of peptide monomers is reached, the 
membrane folds in on itself forming a transient pore (described by a toroidal 
model) (step B). Once a maximum concentration is reached, the membrane 
solubilises because of micellisation causing cell lysis (step C). In the barrel-
stave model (right panel) peptide monomers bind the lipid bilayer as a-helices 
due to hydrophobic interaction (step A). Monomer recognition and assembly, 
even at low surface density of bound peptide, then takes place. Insertion of at 
least two assembled monomers into the membrane initiates pore formation (step 
B). Progressive recruitment of monomers increases the pore size [41]. 
1.6.4 Classifying the mechanism of action of the magainins 
There is a great deal of literature describing various aspects of magainin's mechanism of 
action. The majority of results show magainin to permeabilise membranes via a carpet-like 
mechanism. The following results support this theory. 
The conformation of magainin 2 in water has shown to be random, but on addition of 
trifluoroethanol an a-helix is induced [48]. Raman and Fourier transform infrared 
spectroscopy results were also consistent formation of an a-helix upon binding to lipids, as 
long as the lipids were negatively charged [49]. Furthermore, Raman, fluorescence, and 
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differential scanning calorimetry measurements all indicated that at high and moderate lipid to 
peptide ratios, magainin was orientated parallel to the membrane surface and did not 
significantly disturb the aliphatic chain region [41]. Orientated circular dichroism (OCD) 
measurements, however, showed that peptide orientation depended on the amount of peptide 
bound to the membrane [45]. At low peptide concentrations (expressed as the peptide to lipid 
molar ratio, PIL), the helices were seen to lie parallel to the membrane surface. This has also 
been shown with NMR [39]. However, for PIL above -1/30 a substantial fraction of the bound 
peptide reoriented itself perpendicularly to the plane of the lipid bilayer [45]. Therefore, at 
low peptide concentrations it can be concluded that magainin imbeds itself in the head groups 
of negatively charged acidic lipids and lies parallel to the membrane surface. At higher 
peptide concentrations, neutron in-plane scattering showed that a substantial fraction of the 
peptide reoriented itself perpendicularly to the membrane [41]. Further, neutron in-plane 
scattering experiments, comparing pore formation of alamethicin and magainin 2, indicated 
that magainin 2 formed transient holes which could only be explained by a toroidal type 
model (see section 1.6.3.2) [45, 50]. These experiments therefore indicate that at high peptide 
concentrations, magainin orientates itself perpendicularly to the membrane, forming a toroidal 
channel or pore in the membrane. Occasionally pores were observed at lower concentrations 
because of fluctuation phenomena-they were, however, unstable and short-lived [51]. It can 
be assumed that these pores are similar to transient holes observed at higher peptide 
concentrations. These transient holes would require a lateral expansion in the head. group 
region of the bilayer. Using lamellar X-ray diffraction experiments at concentrations below 
the critical concentration for lysis, the adsorbtion of magainin 2 in the headgroup region was 
noted to expand the membrane laterally, inducing membrane thinning [52]. When a pore is 
closed the participating peptide monomers remain adsorbed to the headgroup region and 
would therefore be expected to surface on either side of the membrane [46]. This was 
supported by experiments showing that the presence of peptide dramatically accelerated the 
flip-flop half-lives of fluorescent lipids [53]. Finally, at high enough concentrations, these 
amphipathic a-helical peptides may cause large-scale membrane permeabilisation due to 
micellisation (Step C in left panel of fig. 1.4). 
Certain aspects of the above mentioned research do not distinguish conclusively between the 
.: "barrel-stave model and the carpet mechanism regarding the mechanism of action of 
magainin 2. For instance, in both models it would be expected to find the peptides in an 
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a-helical conformation, and orientated perpendicularly when interacting with the membrane at 
high concentrations. On the other hand, aspects like limited interaction of the peptide with the 
aliphatic chain region, thinning of the membrane, and peptide translocation can all only be 
described by toroidal holes in the membrane, which occur subsequent to membrane carpeting 
by the peptide. Although this research supports membrane lysis via a carpet-like mechanism, 
it is still not clear whether disruption of the membrane potential due to transmembrane holes 
or micellisation is the cause of cell death. It is also possible that cell lysis is a combination of 
the two, with transmembrane holes initially having a cytostatic effect, and micellisation 
ultimately causing cell lysis. The formation of transmembrane pores by magainin 2 makes this 
peptide ideal for use in conjunction with a conventional antibiotic on cells resistant to the 
antibiotic owing to active efflux pumps. It is postulated that the transmembrane pores will 
provide an additional means of entry into the cell for the conventional antibiotic, and in this 
way overcome the active efflux pumps. 
1.6.5 The effect of alterations to the amino acid sequence on the activity of 
magalnln 
Numerous attempts have been made to improve the activity of magainin so as to enhance its 
prospects as an antibiotic. With the primary and secondary structure of magainin well 
documented, numerous experiments have been performed whereby alterations are made to the 
primary structure so as to enhance the antimicrobial activity of the peptide. 
1.6.5.1 The effect of changing hydrophobicity on the activity of magainin 
The hypothesis that increased hydrophobicity would result in an increased attraction between 
the peptide and the bacterial membrane was tested in the following way. Four peptides were 
synthesised where up to four amino acids were substituted under the following guidelines: (1) 
the four glycine residues of the peptide chain were not replaced because substitution of 
glycine by most other amino acids is expected to enhance helical propensity; (2) the number 
and position of the charged amino acids were maintained to avoid modifications of the 
electrostatic interaction properties; (3) if possible, hydrophobic amino acids were substituted 
by hydrophilic ones, and hydrophilic residues were, replaced by hydrophobic amino acids-
the angles of the hydrophobic and hydrophilic helix domains remained constant; and, (4) the 
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hydrophobic moments' of the peptides were preserved by simultaneous ammo acid 
substitutions in the hydrophobic and hydrophilic cores of the amphiphilic helix [54]. The 
results of this experiment showed that with an increase in hydrophobicity there was a definite 
increase in specificity for a specific target organism. Haemolytic activity, however, increased 
with the same factor as the antimicrobial activity. It has been suggested that the prokaryotic 
specificity of the magainins is the result of the difference in the lipid composition of 
eukaryotic and prokaryotic membranes [55]. Bacterial membranes are rich in negatively 
charged lipids such as phosphatidylglycerol and lipopolysaccharide, while the outer leaflet of 
eukaryotic cell membranes consists predominantly of zwitterionic lipids such as 
phosphatidylcholine and sphingomyelin [56]. Eukaryotic cell membranes also contain 
cholesterol while bacterial membranes do not. It is on this basis of these differences that 
magainins have a high specificity for prokaryotic cell membranes under normal conditions. 
However, once the hydrophobicity of the peptide was increased, the specificity of the peptide 
diminished and the sheer hydrophobic strength of the peptide caused it to bind and lyse 
prokaryotic as well as eukaryotic cell membranes. 
In other experiments, researchers increased the hydrophobicity of the magainin analogue, 
ESF 1, by substituting the arginine residue in position seven for a glycine residue. This 
modification increased the antimicrobial activity of the peptide without affecting haemolysis 
[57]. Besides the increased attraction between the peptide and the bacterial membrane due to 
the increased hydrophobicity, increased activity was also related to stronger a-helix formation 
-',< 
in buffer [57]. 
1.6.5.2 The effect of changing peptide charge on the activity of magainin 
A series of magainin analogues were synthesised with the number of positive charges varying 
from zero to six (peptides termed MGo-MG6+) [58]. In testing the activity of these peptides it 
was noted that the affinity of the peptide for the negatively charged membrane correlated with 
an increase in positive charge of the peptide. In spite of the six positive charges of MG6+ it 
showed even less lytic activity than MG2+, suggesting that an increased positive charge 
perhaps destabilised pore formation [58]. Investigation of pore lifetimes showed them to be in 
the order MG2+;?:MG4+»MG6+. Therefore, an increase in positive charges enhanced the 
binding properties of the peptide, but shortened the pore lifetime. The charge distribution of 
Stellenbosch University  https://scholar.sun.ac.za
1.22 
wild-type magainin 2 seems therefore optimally designed to maximise the lytic activity as 
well as pore lifetime. 
1.6.5.3 Augmentation antibacterial activity of magainin by positive-charge chain 
extension 
Novel magainin 2 analogues were developed by the extension of its chain through the addition 
of segments of positively charged amino acids to either its N or its C terminus and therefore 
increasing its helicity [59]. The activity of magainin 2 towards E. coli, P. aeruginosa, and 
S. aureus was considerably enhanced by these modifications. Its haemolytic activity was only 
moderately affected. 
1.6.5.4 Magainin hybrid peptides 
In order to obtain peptides with improved antimicrobial activities and low haemolytic effects, 
researchers utilised certain properties of separate peptides to develop hybrid peptides. 
Peptides used in the development of hybrid peptides share the common structural feature of 
amphipathic a-helical conformations. One such peptide is the cecropin A-magainin 2 hybrid 
peptide. Cecropin A (isolated from the haemolymph of H cecropia pupae) is composed of 
three different regions: an N-terminal end possessing positively charged lysine residues, a 
central hinge area formed by a Gly-Pro sequence, and a C-terminal hydrophobic stretch [25]. 
Therefore, cecropin A adopts an a-helix-hinge-a-helix conformation in a non-polar 
environment. Because the N-terminal sequence 1 to 12 of magainin 2 is homologous to 
cecropin A (1-12), a novel hybrid was developed by linking cecropin A (1-8) and magainin 2 
(1-12) [60]. The hybrid peptide had no haemolytic activity at a concentration of 100 ~g/mL. 
When compared to the hybrid peptide cecropin A-melittin, it showed similar antimicrobial 
activity against B. subtilis, but showed a two-fold increase in activity against E. coli [60]. 
Further studies have shown the cecropin A-magainin 2 hybrid peptide to possess potent 
antimalarial and antitumor activities [61]. 
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1.6.6 Magainin as a synergistic agent 
1.6.6.1 Functional synergism of the magainins PGLa and magainin 2 
Theories regarding the mechanism of action of these peptides suggest that a peptide oligomer 
is responsible for membrane potential dissipation. The possibility that complexes of a number 
of magainin 2 molecules, or a number of PGLa molecules, are responsible for the action of 
these peptides, suggests that mixed complexes of magainin 2 and PGLa may also form and 
disrupt the membrane potential [62]. In nature X laevis secretes a number of peptides from its 
dermal glands as protection against harmful organisms, and because of the sheer number of 
harmful organisms it seems logical that a degree of synergism exists between some of these 
peptides. Studies using E. coli showed that the combination of PGLa and magainin 2 had a 
much stronger activity than either peptide alone [62]. Synergism was also observed between 
PGLa and magainin 1. Synergism, however, was not a common occurrence between 
membrane active peptides, and not all magainin combinations exhibited synergism [62]. 
Using fluorescence experiments to elucidate the mechanism of synergism between these two 
peptides, researchers found that both peptides form a stoichiometric 1: 1 complex in the 
membrane phase [63]. Single amino acid mutations in magainin 2 significantly altered the 
synergistic activity, suggesting that precise molecular recognition is involved in complex 
formation. 
1.6.6.2 ~-Lactam antibiotics potentiate magainin 2 antimicrobial activity 
Magainin 2 was examined against E. coli grown with and without antibiotics. Bacteria grown 
with sub-lethal concentrations of cefepime, a ~-Lactam antibiotic, were more susceptible to 
the antimicrobial activity of magainin 2 both in buffer and in serum [64]. In addition, in a 
mouse model of E. coli infection, magainin 2 was _completely inactive as a therapeutic agent 
alone. However, it significantly increased the survival of mice when it was administered with 
sub-lethal concentrations of cefepime for the treatment of this systemic bacterial infection 
[64]. It has been shown that a variety of cationic peptides are inhibited by divalent cations 
[65]. In contrast, the antagonistic effect of divalent cations on the antimicrobial activity of 
magainin 2 was significantly lessened when cefepime treated bacteria were examined. It has 
been proposed that the site of divalent cation inhibition of other cationic agents is located in 
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the outer membrane [65]. If this is correct, then it is possible that ~-lactam antibiotics alter 
existing or create new sites in the outer membrane for peptide entry that are less susceptible to 
cation inhibition. The combination of antibiotics and antimicrobial peptides could therefore be 
a feasible approach to eradicating antibiotic-injured bacteria. 
1.6.7 Magainin as a therapeutic agent 
1.6.7.1 Spectrum of tested therapeutic activity 
The broad spectrum of activity of magainin has been recognised by researchers and used in a 
diversity of fields as a potential therapeutic agent. Experiments testing the activity of 
numerous peptides against herpes simplex virus types 1 and 2, showed that magainin 
exhibited no notable activity [66]. Magainin peptides were, however, successful in treating 
melanomas established in athymic nude mice, where melanomas disappeared in six out of 
nine animals tested [67]. The selectivity of magainins for these tumour cells is thought to be 
the result of the relatively large amount of anionic substances such as phosphatidyl serine in 
the tumor cells. These peptides have furthermore shown an~itumour activity against ovarian 
and lung cancer cell lines [68, 69]. The magainin peptides also exhibited potential as food 
preservatives, showing significant antimicrobial activity against a variety of foodborne 
pathogens [70]. In other studies magainin was successfully tested as a potential contraceptive 
agent. Experiments showed that when magainin A was applied intravaginally to rats before 
mating on the proestrusestrus day, complete arrest of sperm motility with 200 f.lg 
concentration was observed, and none of the treated females conceived after treatment [71]. 
Furthermore, magainin A had the advantage over current spermicides in that it had no 
irritating effects on the vagina and provided additional protection against acquired infections 
caused during sexual intercourse [71]. 
1.6.7.2 Magainins as broad-spectrum topical and systemically administered antibiotic 
agents 
MSI-78 IS a 22 ammo acid analogue of magainin 2, which evolved through extensive 
structure-activity studies of the natural peptide. This molecule exhibits potent antibiotic 
activity against a wide variety of Gram-positive, Gram-negative, anaerobic, and fungal 
pathogens [72]. In October 1992, MSI -78, formulated as a topical preparation, entered Phase I 
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clinical trials, a phase of evaluation in which human safety is established. A good safety 
profile emerged and in February 1993 Phase II studies were initiated. These studies were 
designed to determine whether the formulated preparation of MSI-78 could effectively reduce 
dense bacterial flora indigenous to the perineal area from healthy human volunteers. In a study 
involving 45 subjects, application of the peptide at concentrations ranging from 0.5% to 2.0% 
significantly reduced all species of bacteria and yeast by several orders of magnitude [72]. 
The antibacterial effect of a single application persisted through 24 hours. On the basis of 
these findings, MSI-78 entered Phase lIb/III clinical trials in June 1993, to be evaluted as a 
topical preparation for the treatment of impetigo, a serious skin infection commonly seen in 
children. Current available information only dates to March 18, 1997, which announced the 
successful results of the second, pivotal Phase III clinical trials of MSI -78 for the treatment of 
infection in diabetic foot ulcers [73]. 
Many researchers have also started to explore antimicrobial peptides as systemically 
administered agents. In these experiments, bacterial infections are introduced in mice, which 
are then subsequently treated with intravenously administered antibiotics. Several antibiotic 
peptides did in fact exhibit activity in the in vivo infection model [72]. The development of 
peptide antibiotics as systemic therapeutics will naturally lag behind their development as 
topical agents because of the extensive evaluation of toxicity required for this human 
application. 
1. 7 Discussion 
Multidrug resistance has clearly become a global crisis, and new and unique methods will be 
imperative in combatting this problem. One of the most ingenious mechanisms of resistance 
utilised by resistant bacteria is the general mechanism of an outer membrane barrier 
functioning synergistically with an active efflux pump. To overcome this form of resistance it 
would be necessary to remove the functional synergism that exists between these two 
components. 
We propose to use the antimicrobial peptide magainin 2 in conjunction with a conventional 
antibiotic, tetracycline, against tetracycline resistant E. coli in attempt to overcome the 
tetracycline resistance that is incurred through active efflux pumps. The mode of action, broad 
spectrum of activity, structural versatility, and therapeutic qualities make the magainin 
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peptides ideal candidates for this study. The synergistic qualities of magainin with other 
peptides and antibiotics has already been described. Of major interest was the ability of 
fJ-Iactam antibiotics to potentiate the antimicrobial activity of magainin 2 (section 1.6.6.2). 
Synergy between these two antibiotic agents was hypothesised to result from the 
permeabilising effect of the peptide, which disturbed the integrity of the bacterial outer 
membrane and facilitated entry of the antibiotic into the bacterial cell [72]. Therefore, we 
intend to use the same synergistic approach on bacteria that expel the antibiotic as a 
mechanism of resistance. It is hoped that the permeabilising effect of magainin 2 on the 
bacterial outer membrane will facilitate the entry of tetracycline into the cell to such a degree 
that the active efflux pumps will be neutralised and the bacteria will once again become 
susceptible to the tetracycline. 
The following chapters shall describe the synthesis of the antimicrobial peptides (Chapter 2), 
the development and evaluation of an antimicrobial assay (Chapter 3), and the investigation of 
the synergy between the antimicrobial peptides and a conventional antibiotic on resistant 
organisms (Chapter 4). Finally, general implications and future prospects of this work are 
discussed in Chapter 5. 
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Chapter 2 
Synthesis and purification of m again in 2 and N-terminal 
deletion analogues 
2.1 Introduction 
2.1.1 Solid phase peptide synthesis 
2.1 
The synthesis of peptides has been a challenge to organic chemists since the tum of the 
century. Numerous breakthroughs have been made this century, with the most notable and 
earliest being the synthesis of the lactogenic nonapeptide amide hormone oxytocin by Du 
Vigenaud and his co-workers in the early 1950s, initiating a new era in both biology and 
chemistry [1]. New biologically active compounds were being isolated regularly, requiring 
new and improved methods for their synthesis. At this stage the classical method of solution 
phase peptide synthesis was hard pressed to meet the explosive increase in demand. Although 
successful, this method of synthesis provided only modest yields owing to a high rate of side 
chain modifications. It was R.B. Merrifield who subsequently developed solid phase peptide 
synthesis (SPPS) in 1959 [2], which has since proven to be the method of choice for 
synthesising peptides and small proteins. 
Since the conception of SPPS, the chemistry developed by Merrifield has remained fairly 
standardised. The protocol uses a chemical scheme based on graduate acidolysis [3]. The 
Merrifield peptide synthesis proceeds as follows: 
1. Covalent attachment of an N-a-tert.-butyloxycarbonyl (tBoc) amino acid to functionalised 
crosslinked polystyrene resin beads. The tBoc group protects the N-terminus of the amino 
acid being attached, so as to prevent polymerisation; 
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2. Removal of the acid labile tBoc group with trifluoroacetic acid (TF A) and neutralisation 
of the free amino terminus with triethylamine (TEA); 
3. Coupling the second tBoc-amino acid to the free amino terminus of the resin bound amino 
acid via a carbodiimide activating agent. Throughout this procedure, side-chain protection 
of the coupled amino acids is conferred by ether, ester and urethane derivatives based on 
benzyl alcohol with electron-withdrawing halogens for greater acid stability. Other 
side-chain protection schemes are based on ether and ester derivatives of cyclopentyl and 
cyclohexyl alcohol; 
4. Cleavage of the peptide and removal of the side-chain protection groups is carried out 
with hydrogen fluoride (HF) in the presence of suitable scavengers that trap reactive 
carbonium ions and thereby prevent them from undergoing deleterious side-reactions with 
sensitive amino acids [4]. 
Although successful in synthesising peptides of high purity, repetitive TF A acidolysis, 
required for the deprotection of the tBoc amino blocking group, often leads to the alteration of 
sensitive peptide b·onds as well as acid catalysed side-reactions [4]. Furthermore, HF used for 
cleavage of the peptide from the resin is not only costly, but also extremely dangerous, and 
requires the use of expensive protective laboratory apparatus. 
It was from these concerns that fluoronylmethoxycarbonyl (Fmoc) chemistry was developed 
by Atherton, Sheppard and Dryland [5]. This protocol substituted the acid-labile tBoc-amino 
protective group, used in the Merrifield synthesis protocol, with a base-labile N9-Fmoc-group, 
which required only mild basic removal conditions. This base labile Fmoc-group could 
rapidly be removed in a l3-elimination reaction brought about by secondary amines such as 
piperidine, which also scavenged the dibenzofulvene intermediate, preventing back-addition 
to the peptide chain. Peptide synthesis according to the Fmoc protocol proceeds as follows: 
1. Covalent attachment of an Fmoc-amino acid to a rigid solid phase consisting of 
functionalised dimethylacrylamide polymerised within Kieselguhr (marketed as Pepsyn K 
or Novasyn ®K); 
2. Removal of the base labile Fmoc group using piperidine; 
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3. Coupling of the second ammo acid to the resm bound ammo acid after activation. 
Activation can take place in a number of ways: First, activation can take place by the 
formation of an active anhydride. Carbodiimides such as dicyclohexylcarbodiimide (DCC) 
and diisopropyicarbodiimide (DIPCIDI) are often used in this type of in situ activation. 
During the coupling reaction I-hydroxybenzotriazole (HOBt) can be used to prevent 
racemisation and dehydration of the acid amide side-chains of asparigine and glutamine. 
Second, pre-activated amino acid esters can be used. Examples of active esters include 
p-nitrophenyl [6], 3,4-dihydro-4-oxo-l,2,3-benzotriazin-3-yl (Dhbt) [4, 6], and 
pentafluorophenyl (Pfp) esters [4, 6, 7]. Amino acid esters are generally used with HOBt 
as acylation catalyst [4, 8]. Third, another type of in situ activation can be performed using 
benzotriazol-l-yl-oxy-tris-dimethylaminophosphonium hexafluorophosphate (BOP) 
[9, 10], or its lesser toxic analogue, benzotriazol-l-yl-oxy-tris-pyrrolidinophosphonium 
hexafluorophosphate (PyBOp®). These reagents react with the ~-protected amino acids in 
the presence of a base to form highly active oxybenzotriazolyl esters [8]. During coupling, 
side-chain protection is conferred by tertiary butanol based ether, ester and urethane 
derivatives. 
4. Cleavage of the peptide, and removal of the side-chain protection groups, is carried out 
with TF A in the presence of suitable scavengers that trap reactive carbonium ions and 
thereby prevent them from undergoing deleterious side-reactions with sensitive amino 
acids [4]. 
The Fmoc-polyamide protocol was used for synthesis purposes because of its milder chemical 
approach, and because it is a well-established method in our laboratory. 
2.1.2 Synthetic antimicrobial peptides 
Synthetic antimicrobial peptides have played a major role in developing the antibiotic 
potential of antimicrobial peptides [11, 12, 13]. A vast amount of information regarding the 
structure-function of these peptides has been deduced from synthetic antimicrobial peptide 
analogues and deletion peptides. Because of its unique and well documented mechanism of 
action, as well as its broad-spectrum of activity and lack of toxicity, magainin 2 (Table 2.1) 
was synthesised for future research (see Chapter 1). Two N-terminal deletion analogues 
(Table 2.1) were also synthesised. The first of the deletion peptides differed from the full 
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length peptide by the omission of two amino acid residues from the N-terminal ofmagainin 2, 
while the second deletion peptide had four residues omitted from the N-terminal (termed 
magainin 2 N 21 , and magainin 2 N 19 respectively). The N-terminal deletion analogues were 
synthesised to determine the importance of the N-terminal of the peptide with regards to 
antimicrobial and membrane activity. Two syntheses were performed, with the second 
synthesis being an optimisation of the overall synthesis and purification procedure of the 
peptides. 
Table 2.1 Primary structures ofmagainin 2 and the two N-terminal deletion peptides. 
Peptide Amino acid sequence Mr 
magainin 2 GIGKFLHSAKKFGKAFVGEIMNS 2466.93 
magainin 2 N21 GKFLHSAKKFGKAFVGEIMNS 2296.72 
magainin 2 N 19 FLHSAKKFGKAFVGEIMNS 2111.49 
2.2 Materials 
2.2.1 General reagents and solvents 
N, N' -dimethylformamyde (DMF; 99.5%), potassium hydroxide (KOH), sodium carbonate 
(anhydrous) and self-indicating silica gel were from Saarchem (Krugersdorp, South Africa). 
Trifluoroacetic acid (TF A; >98% and 99.5%), glacial acetic acid, chloroform (>99%), diethyl 
ether (99.5%), ethanol (99.8%), butan-l-01 (99.5%), pyridine (99.5%), n-hexane (99.8%), 
potassium cyanide (KeN), di-phosphorous-pentoxide, 2',7' -dichlorofluorescein, ninhydrin, 
, 
molecular sieve (3A), aluminium oxide 90 and Kieselgel 60-F254 thin layer plates were from 
Merck (Darmstadt, Germany). Piperidine (98%), ethyl acetate (99.8%), 1,4-dioxan (99.8%), 
and 2-methylbutan-2-01 (t-amyl alcohol; 98%) were from BDH Chemicals (Poole, UK). TFA 
(>98%) and piperidine (98%) were also purchased from Sigma Chemicals Co. (St. Louis, 
USA). Fluka Chemicals (Buchs, Switzerland) supplied I-fluoro-2,4-dinitrobenzene (FDNB), 
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1,2-ethanedithiol (>98%), and thioanisol (>99%). High purity dry nitrogen gas was from 
Afrox (South Africa). 
2.2.2 Reagents for peptide synthesis 
Pepsyn KA resin (0.2 meq/g), Fmoc-L-Ser(tBu)-Odhbt, Fmoc-L-Asn-OPfp, Fmoc-L-Asn-OH, 
Fmoc-L-Ile-OPfp, Fmoc-L-Met-OPfp, Fmoc-L-Glu(OtBu)-OPfp, Fmoc-L-Gly-OPfp, Fmoc-
L-Val-OH, Fmoc-L-Phe-OPfp, Fmoc-L-Ala-OPfp, Fmoc-L-Lys(Boc)-OH, Fmoc-L-His(Boc)-
OPfp were from Milligen-Millipore (Milford, USA). Fmoc-L-Ser(tBu)-OH, Fmoc-L-Leu-OH 
and pentafluorophenol were from Sigma Chemical Co. (St. Louis, USA). Benzotriazol-l-yl-
oxy-tris-pyrrolidinophosphonium hexafluorophosphate (PyBOP®) was from Calbiochem-
Novabiochem Co. (La Jolla, USA). N, N' -dicyclohexylcarbodiimide (DCC) was from Merck 
(Darmstadt, Germany). Fluka Chemicals (Buchs, Switzerland) supplied I-hydroxy-
benzotriazole (HOBt) and N, N' -diisopropylethyl amine (DIPEA). 
2.2.3 Reagents and solvents for amino acid analysis and chromatography 
Constant boiling hydrochloric acid (HCI, 30%), sodium acetate (99.5%) and phenol (99,5%) 
were from Merck (Darmstadt, Germany). Phenylisothiocyanate (PITC) and amino acid 
standards were from Pierce Chemicals (Rockford, USA). Ethylenediaminetetraacetic acid 
tetrasodium salt dihydrate (EDTA, >98%) was from Fluka Chemicals (Buchs, Switzerland). 
Methanol (HPLC-grade, UV cut-off 20Snm) and acetonitrile (HPLC-grade, UV cut-off 190 
nm) were from Romil LTD (Cambridge, UK). Pico-Tag® sample diluent, Nova-Pak CI8 
analytical HPLC columns, 0.45 mikron HV membrane filters were from Waters-Millipore 
(Milford, USA). Polygosil (C I8, 60 A, irregular particle size) packing material, used to prepare 
the semi-preparative HPLC column, was· from Macherey-Nagel (Duren, Germany). High 
quality triethylamine (TEA) was from Aldrich Chemical Co. (Gillingham, UK). CM 
Sepharose CL-6B cation exchange resin was from Sigma Chemical Co. (St. Louis, USA). 
Sephadex G-IO resin was from Pharmacia Fine Chemicals (Uppsala, Sweden). Analytical 
grade water was prepared by filtering glass distilled water through a Millipore Milli Q® water 
purification system. 
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2.2.4 Drying and storage of reagents and products 
Fmoc-amino acids and peptide synthesis resins were stored at 4DC in desiccators with silica 
gel as drying agent. The FDNB was stored at <1 ODC, while PYBOp® and HOBt were stored at 
_20DC, with silica gel as drying agent. Before use, amino acid derivatives, resin, PYBOP®, 
and HOBt were dried overnight under high vacuum, with di-phospherous-pentoxide as drying 
agent. The DMF was stored on molecular sieve (3A) at room temperature in amber bottles. 
PITC, DIPEA and amino acid standards were stored at _20DC, while TEA (high quality for 
amino acid analysis) was stored at <lODC, all under N 2-atmosphere. Lyophilised peptides were 
stored under vacuum in a desiccator with silica gel as drying agent at 4 DC. All other reagents 
were stored at room temperature. 
Detergents, such as regular cleaning agents, can influence the activity of antimicrobial 
peptides. Therefore, glassware returned from the initial wash, was rinsed three times with 
distilled water, three times with 60% ethanol, three times with analytical grade water, and 
finally placed in an oven to dry at temperatures ranging between 110 and 140DC. Vials used in 
peptide synthesis were pyrolised at 565- 570D C. 
2.3 Methods 
2.3.1 Preparation of solvents 
2.3.1.1 Distillation of N, N'-dimethylformamide 
It is important that freshly distilled, highly pure DMF, which is the principal solvent used in 
Fmoc-polyamide solid phase peptide synthesis, be used at all times. Impure DMF can be 
contaminated with secondary amines and H20, which in turn cause the loss of the Fmoc- and 
active ester groups of the peptide. DMF reacts with water to form dimethylamine and formic 
acid [14, 15]. 
Undistilled DMF was shaken up with 10-20 giL dry potassium hydroxide pellets to remove 
residual water, or the DMF was stored for at least one week on activated molecular sieve 
(3A). Impurities such as volatile secondary amines were removed by fractional distillation 
under vacuum (high vacuum pump, 5-10 mm Hg) and a dry nitrogen bleed. The first 10-15% 
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of the distillate was discarded and the constant boiling fraction (4S0C at 10 mm Hg) was 
collected. Only DMF which passed Sanger's test for amines was used (see below), otherwise 
it was redistilled. 
2.3.1.2 Sanger's test for amines 
Secondary amines present in DMF can cleave the base labile Fmoc-group from the N-
terminus of the peptide. Sanger's test for amines was used to determine the quality of the 
DMF prior to use [16]. It was performed by mixing equal volumes FDNB (1.0 mglmL in 9S% 
ethanol) and DMF, incubating the mixture at room temperature for 30 minutes, and then 
determining the absorbance of the reaction mixture at 381 run. A O.S mglmL FDNB in 9S% 
ethanol solution was used as blank. An acceptable blank's absorbance was in the region of 0.2 
absorbance units. For synthesis purposes, DMF with an absorbance of between 0.02S and O.OS 
units higher than the blank was used in the coupling procedure as well as the washing steps 
prior to the coupling procedure. Lower quality DMF with an absorbance of between O.OS and 
0.08 units higher than the blank was used for the other washing steps. To ensure the removal 
of all traces of piperidine (used in the deblocking steps during the peptide synthesis protocol), 
. the Sanger test was performed on DMF samples from the final washing step. The samples 
were in most cases only incubated for 2 to 3 minutes and compared to a blank solution. Clean 
samples were deemed to be no more than 0.01 units higher than the blank solution. 
2.3.1.3 Distillation of piperidine and pyridine 
For the same reasons as DMF, piperidine was required to be of high purity. Piperidine was 
distilled over dry potassium hydroxide (10 to 20 gIL) and dry nitrogen bleed at atmospheric 
pressure. The first 10-lS% of the distillate was discarded and the constant boiling fraction 
(10S0C) was collected. The distilled piperidine was stored in dark bottles and used within 
three months [14]. Pyridine for use in Kaiser-ninhydrin test was purified in the same manner. 
2.3.1.4 Distillation of N, N'-diisopropylethyl amine 
N, N'-diisopropylethyl amine was initially distilled over ninhydrin (1-2 giL) and then 
redistilled over dry potassium hydroxide pellets (5-10 giL). Distillation was performed at 
atmospheric pressure under a dry nitrogen bleed. A small forerun was discarded, and the 
fraction with boiling point between 12S-127°C was collected. Small volumes (4 mL) were 
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aliquoted in amber vials, flushed with dry N2, sealed tightly and stored at _20DC. Only small 
volumes were distilled because of the instability of the mixture [6]. 
2.3.2 Preparation and quality control of the amino acid derivatives 
2.3.2.1 Thin layer chromatography (TLC) 
Thin layer chromatography was performed on aluminium backed Kieselguhr 60-F254 TLC-
plates. A mobile phase containing chloroform:methanol:acetic acid (85: 10:5) was used for the 
Fmoc amino acids, and chloroform:methanol (85:10) was used for the Fmoc amino acid Opfp 
esters. Acetic acid was not used with Fmoc amino acid Opfp esters as it cleaved the Opfp 
group [17]. Initially the plates were visualised under UV-light (268 nm). Once dry they were 
sprayed with 0.2% ninhydrin in 95% ethanol and developed at 110°C for 10 minutes to detect 
residual amino groups. Derivatives were used for synthesis if they exhibited a single spot with 
the correct Rr value. 
2.3.2.2 Melting point determination 
Before a synthesis the ~elting points of the derivatives and catalysts (PyBOp®, HOBt) were 
determined. A small amount of derivative was placed in the bottom of a capillary tube and the 
melting range was determined using a Gallenkamp melting point apparatus. Amino acid 
derivatives used for synthesis had to be within 5°C of their literature values [18]. 
2.3.2.3 Purification of Fmoc amino acid derivatives 
Kaiser positive samples (section 2.4.3.4), or samples with an incorrect melting point were 
purified and re-evaluated prior to a synthesis. Fmoc-amino acids without acid labile side chain 
protection were suspended in 1 % acetic acid (or 0.1 % acetic acid if an acid labile side chain 
protection group is present) and the precipitate collected by filtration. The precipitate was then 
washed with water, ice-cold methanol, ethyl acetate, and diethyl ether and dried thoroughly 
under vacuum. If the Kaiser test remained positive, the derivative was recrystalised from 
hexane/ethyl acetate. The Pfp esters were recrystalised from hexane and/or washed with ice-
cold ethyl acetate and n-hexane. 
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2.3.2.4 Synthesis of Fmoc amino acid pentafluorophenyl esters 
The pre-activation of Fmoc-Asn-OH and Fmoc-Gln-OH to form their pentafluorophenyl (Pfp) 
ester was necessary, because other activation procedures, such as with PyBOp® and DCC can 
lead to the formation of aspartimides and glutamides [4]. A method described by Atherton et 
al [6], and adapted by Rautenbach [15] was used for the synthesis of Fmoc-Asn-OPfp. Prior to 
the synthesis, the Fmoc-L-Asn-OH showed a positive Kaiser test, and was therefore washed 
as described in section 2.4.2.3. A 96% yield of the derivative was obtained after washing, and 
a negative Kaiser test indicated that the majority of the impurities had been removed. The 
synthesis then proceeded as follows: Fmoc-L-Asn-OH (3.42 g; 9.6 mmole) was dissolved in 
13 mL dioxan, and the pentafluorophenol (2.09 g; 11 mmole) in 4 mL dioxan. The two were 
combined and allowed to cool in an ice-bath. Dicyclochexylcarbodiimide (2.18 g; 11 mmole) 
in 8 mL dioxan was added drop-wise to the stirring slurry. After reacting for 75 minutes, the 
white creamy slurry was further diluted with 27 mL dioxan. The dilute slurry was then 
allowed to react for a further 23 hours at room temperature. The solution was filtered to 
remove the white dicyclohexylurea precipitate. The precipitate was washed with 3xlO mL 
dioxan and the combined filtrate was evaporated under vacuum. The addition of n-hexane lead 
to the formation of slightly yellow crystals, which were washed with ethyl acetate and 
methanol and dried under vacuum. Melting point determination (154-156°C) and TLC 
(~=0.7) showed that the amino acid pentafluorophenyl ester had successfully been 
synthesised. A 52% yield of the derivative was obtained. Both the commercial and the 
synthesised product contained a small amount of Fmoc-L-Asn-OH. 
2.3.3 Synthesis of the peptides 
The peptides were synthesised at room temperature (20-25°C) according to the Fmoc-
polyamide protocol using a shake flask procedure [15]. Two syntheses were done, with the 
second being an optimisation of the synthesis and purification procedures of magainin 2 and 
the deletion peptides. The protocol for a complete cycle of operations including washing, 
coupling, deblocking, and sampling steps is set out in Table 2.2. 
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2.3.3.1 Coupling of the first amino acid 
Pepsyn KA-resin (capacity of 0.2 milli-equivalent per gram resin) was used in the syntheses, 
to which the first amino acid was coupled via the PyBOp® method (described hereafter). The 
coupling efficiency was evaluated using the Fmoc-test (section 2.4.3.5), and the coupling step 
was repeated until the resin was completely saturated. Prior to synthesis the resin was swollen 
for approximately 20 minutes in high purity DMF (20 mUg). 
2.3.3.2 Elongation of the peptide chain 
For the elongation steps, the required reagent quantities were calculated from the reSIn 
capacity (0.2 milli-equivalent per gram of dry resin). Fmoc-amino acid OPfp esters were 
coupled with HOBt as catalyst and trapping agent [4, 8], each at a three fold molar excess. 
Fmoc-amino acids were coupled using the PyBOp® reagent in the following manner: a three 
fold molar excess of the protected amino acid and HOBt, were each dissolved in a minimum 
volume of DMF (0.5-1 mL), combined, and initially added to the resin. Following this, 
PyBOp®, at a 3 fold molar excess, was mixed with a 6 fold molar exces.s ofDIPEA, both in a 
minimum volume DMF (0.5-1 mL), and the combination also added to the resin [15, 19]. 
Compl~te acylation varied from 60 to 90 minutes, as determined with the Kais~r test and/or 
the Fmoc test. 
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Table 2.2 Operations for one cycle of the peptide synthesis procedure [Table reproduced 
with permission from 15]. 
Synthesis step Time Volume Monitoring Comment 
1. Swelling of resin 20 min. 4 bed volumes bedvolume = 
5mLlgram resin 
2. Anchoring of first 2 hours <1/2 bed volume Fmoc-test Refer to sections 
amino acid via 2.3.3.1 and 2.3.3.5 
activated Fmoc-
amino acid to resin 
3. DMF wash 6 X 3 bed Absorbance at 31 Onm Absorbance must be 
volumes zero 
4. Resin sample A l. Kaiser test (2.3.3.4) l. If test not negative, 
extend or repeat 
coupling step in 
(ii. Amino acid analysis; elongation. 
2.3.5.3) 
ii. Amino acid 
analysis is used in 
monitoring 
anchoring step 
5. Removal of Fmoc 30 min. 3 bed volumes Absorbance at 290nm Refer to sections 
group (deblocking) ~ 2.3.3.3 and 2.3.3.5 
with 20 % piperidine 
inDMF 
6. DMFwash 10X3 bed ~ 
volumes 
7. DMF wash sample 0.5 ml Sanger test Wash until test is 
negative (2.3.1.2) 
8. Resin sample B l. If test not positive, 
repeat deblocking 
ii. Post synthesis 
evaluation 
9. Coupling of next 60 min. <1/2 bed volume. Refer to 2.3.3.2. 
amino acid via Repeat steps 3 and 9 if 
activated Fmoc- necessary 
amino acid 
1 O.Repeat steps 3 to 8 
11.Repeat steps 9 and 
10 for a-amino acids 
III sequence 
12. Washing and drying Refer to 2.3.3.3 
of resin 
13 . Liberation of peptide Refer to 2.3.3.3 
acid from resin 
Stellenbosch University  https://scholar.sun.ac.za
2.12 
2.3.3.3 Removal of the Fmoc-group from the attached amino acid 
Once coupling was completed (as shown by a negative Kaiser test) the resin was washed 
thoroughly to remove the active amino acid derivative and catalyst. To remove the Fmoc-
group from the coupled amino acid, three bedvolumes of piperidine (20% in DMF) was added 
to the resin for a period of 30 minutes. After each deblocking step, the absorbance of the 
piperidine mixture was recorded at 290 nm. Absorbance readings at 290 nm were compared to 
readings obtained from previous deblocking steps to show the extent of deblocking. On 
removal of the piperidine, the resin was washed thoroughly with DMF until an acceptable 
Sanger test was obtained (section 2.3.1.2). 
2.3.3.4 The Kaiser test 
The Kaiser test is specific for primary amino groups [20]. Three solutions make up the test: 
(a) 500 mg ninhydrin in 10 ml 95% ethanol, (b) 40 g phenol in 10 ml 95% ethanol and (c) 2 
ml 0.001 M KCN solution diluted to 100 ml with distilled pyridine. The Kaiser test was used 
during peptide synthesis to evaluate the deblocking, as well as the coupling of an amino acid. 
The test proceeds as follows: a few resin beads (4 to 5) were dried using diethyl ether, after 
which three to five drops of each solution were added to the beads. The reaction mixture was 
then incubated for 5 minutes in a water bath at 80-90DC. The colour of the resin beads and 
reaction mixture was evaluated using a magnified eyepiece. A positive result, as expected 
after deblocking, usually entailed the beads becoming dark blue. A negative result, as 
expected after coupling, showed no change in the colour of the beads. 
Quality control of the Fmoc-amino acid derivatives was also done using the Kaiser test. Five 
milligrams of the dried derivative was dissolved in 100 ilL DMF, after which 100 ilL of each 
of the Kaiser test solutions were added. Colours were evaluated after 5 minutes incubation at 
90DC. To determine the extent of contamination of a derivative, its Kaiser test result was 
compared to a standardised colour chart. 
2.3.3.5 The Fmoc-test 
To evaluate the coupling of a Fmoc amino acid, and specifically the coupling of the first 
amino acid, the UV absorbance character of the liberated Fmoc-fulveen group was exploited 
[4,21]. A test was devised whereby the concentration of Fmoc-groups released subsequent to 
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the deblocking step could be used to calculate the percentage coupling. This test proved to be 
very useful in replacing the other alternative, amino acid analysis, a time consuming 
procedure. 
In developing the Fmoc-test a 0.1 mmole concentration of Fmoc-Ieucine was treated with 10 
mL of 20% piperidine in DMF for 15 minutes to release the Fmoc-group. The 20% piperidine 
in DMF was removed, diluted a 100 times with DMF, and used in a dilution series (triplicate 
determinations per concentration value). The absorbance of sample in the dilution series was 
determined at 290 nm using DMF as a blank. The linear relationship between the percentage 
liberated Fmoc and absorbance at 290 nm was as follows: 
A Z90 = 0.002848 x % liberated Fmoc-groups -0.009975 
To evaluate a coupling step, 10-15 mg of resin was removed and dried for an hour. The resin 
was weighed analytically and then deblocked with a volume of 20% piperidine in DMF; 
equivalent to 20 mL per 0.1 mmole of expected Fmoc groups. After deblocking, a 100 times 
dilution (triplicate determinations) was made of the deblocking mixture and the absorbance 
determined at 290 nm. The absorbance values were entered into the previously determined 
standard curve equation and the percentage coupling determined. 
2.3.3.6 Removal of the completed peptide from the resin 
After the deprotection and DMF wash of the final amino acid, the resin was washed with t-
" 
amyl alcohol, glacial acetic acid, again t-amyl alcohol, and finally dried with diethyl ether 
[4,6, 17]. For the first synthesis, the peptides were cleaved from the resin using 95% TFA, 
5% phenol, and methionine (1 g/50 mL). The resin was treated with this cleavage cocktail for 
three hours 1 at room temperature with occasional stirring. For the second synthesis, the 
peptides were cleaved from the resin using reagent K (82.5% TF A, 5% phenol, 5% H20, 5% 
thioanisol, and 2.5% 1,2-ethanedithiol) [22]. After treatment with the respective cleavage 
cocktails, the resin was removed by filtration and washed with TF A, glacial acetic acid, and 
analytical grade water. The resin was then washed with ether, dried and analysed for'amino 
acids to determine the extent of peptide cleavage. The filtrate containing the peptide was 
I The reaction time depends mainly on the sequence of the peptide and the type of side chain protection [4]. 
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concentrated under vacuum on a Buchi Rotavapor at 45°C. The peptide concentrate was 
dissolved in 50 mL analytical grade water and by-products were extracted three times with 50 
mL diethyl ether. The combined ether fractions were then washed with 50 mL analytical grade 
water to recover any peptide in the ether. The combined aqueous fractions were freeze-dried. 
2.3.4 Purification of the peptides 
2.3.4.1 Gel permeation chromatography 
Peptides were initially purified by Sephadex G 10 gel permeation chromatography usmg 
analytical grade water was used as eluant. Freeze-dried crude peptides were dissolved in an 
amount of water corresponding to 10% of the column bedvolume, their absorbance measured 
at 230 nm and 257 nm 2 and then loaded onto the Sephadex G 10 column. Flow rates were 
10 to 14 mLlhour, and the eluates were monitored at 230 nm or 257 nm. The major absorbing 
fractions were collected and freeze-dried. 
2.3.4.2 Cation exchange chromatography 
A CM Sepharose CL-6B column (25 x 1.5 cm) was used for further purification. A 
0.35 - 0.45M ammonium acetate (PH 6.00) gradient successfully eluted the peptides and was 
therefore used for further purifications. 
Before use, the column was regenerated by running a linear 0.35-0.45M ammonium acetate 
(PH 6.00) gradient, and then equilibrated with three bedvolumes of 0.35M ammonium acetate 
(pH 6.00). Freeze-dried cationic peptide preparations were dissolved in the equilibration 
buffer and then loaded onto the column. The flow rate was 14 mL/hour. Elution was started 
with the equilibration buffer, and after an hour (14 mL) a linear gradient was introduced, with 
the highest concentration ammonium acetate, 0.45 M (pH 6.00), as the final concentration. 
The eluted fractions were monitored at 230 nm and 257 nm and the major absorbing fractions 
were collected and freeze-dried. 
2 Phenylalanine, an amino acid in the magainin 2 sequence, absorbs maximally at 257 nm. 
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2.3.4.3 High performance liquid chromatography 
As peptides at a purity of >96% were required, semi-preparative HPLC was used as the final 
purification step. Peptide samples (5 mg/mL) were dissolved in 50% acetonitrile in analytical 
grade water. Prior to use, all samples were centrifuged for 5 minutes at--l000 g to remove 
undissolved particles. The HPLC system was comprised of the following components: two 
Waters 510 pumps, a Waters Model 440 detector (monitoring at 254 nm), a WISP 712 sample 
processor, a MAXIMA software controller system, and a semi-preparative C I8 Polygosil 
HPLC column (irregular particle size, 60 A pore size, 250 mm x 10 mm). A linear gradient 
(3 mL/min flow rate) was created using eluant A (0.1 % TF A) and eluant B (90% acetonitrile 
and 10% A) as shown in Table 2.3 [14, 17]. Peptide fractions were collected, and freeze-dried 
for further analysis. 
Table 2.3 Gradient program used for the chromatography of the peptides. 
Flow rate; preparative Flow rate; analytical 
Time (min) HPLC (mL/min) HPLC (mL/min) 0/0 A %B 
0 3.0 1.0 80 20 
1 3.0 1.0 80 20 
13 3.0 1.0 0 100 
14 3.0 1.0 0 100 
20 3.0 1.0 80 20 
25 3.0 1.0 80 20 
. 2.3.5 Analysis of the purified peptides 
2.3.5.1 Analytical high performance liquid chromatography 
Analytical reverse phase high performance liquid chromatography was used to determine the 
purity of the synthetic peptides. A CI8 Nova-Pak HPLC column was used with the system 
described under section 2.3.4.3. The chromatography was monitored at 254 nm. The same 
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gradient was employed as for preparative HPLC, but the flow rate was reduced to 1.0 
mLiminute (Table 2.3). 
2.3.5.3 Amino acid analysis 
Amino acid analyses were done using a pre-column derivatisation with phenylisothiocyanate 
(PITC), according to the Pico-Tag® method [23, 24]. Samples to be analysed were thoroughly 
dried under vacuum. Gaseous phase hydrolysis was done under a nitrogen atmosphere using 6 
N HCI containing 1 % phenol. Gaseous phase hydrolysis took place for 24 hours at 110°e. A 
shortened hydrolysis procedure (150°C, 1 hour) could also be used if necessary. Hydrolysed 
samples were dried under vacuum to remove all traces of the acid. Following this, the 
hydrolysed samples were "re-dried" by adding ethanol:water:TEA (1:2:1) (10 uL) to each 
sample to obtain an optimal pH for derivatisation. The re-drying solution was removed under 
vacuum, and 20 ~L of a derivatisation solution containing methanol:TEA:water:PITC 
(7: 1: 1 : 1) was added to each of the samples. Samples were derivatised for 10-20 minutes at 
room temperature before being dried under vacuum. Dried samples were dissolved in an 
, . 
appropriate amount (200 uL) ofPico-Tag® diluent and filtered through HV 0.45 ~m Millipore 
filters. 
Samples were chromatographed at 44°C using a Nova-Pak CIS HPLC column (150 mm x 3.9 
mm) using the previously described HPLC system (section 2.3.4.3). Derivatised amino acids 
and a Pierce standard amino acid mixture (hydrolysis standard) were separated with a binary 
non-linear gradient using eluant A (0.14 M sodium acetate, 10 mM EDTA and 0.5 mL TEA 
per litre, titrated to pH 6.40 with acetic acid and then mixed with 6% acetonitrile) and eluant 
B (60% acetonitrile containing 10 mM EDTA) [23, 24]. The standard amino acid mixture 
. (hydrolysis standard) was used to calibrate the analysis. 
2.3.5.4 Mass spectrometry 
A Micromass Quattro triple quadropole mass spectrometer fitted with an electrospray 
ionisation source was used for electro spray ionisation mass spectrometry. Peptide samples 
were dissolved in 50% acetonitrile in water. Ten ~L (2 ng peptide in 50% acetonitrile/water 
containing 0.05% TFA) of the sample was introduced into the ESI-MS at 20 ~Llminute, with 
applied capillary voltage of 3.5 kV using a Rheodyne injector valve. The cone voltage was 70 
V with the skimmer lens offset at 5 V. The source temperature was 80°C. Data were aquired 
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in the positive mode for these cationic peptides, scanning the first analyser (MS,) through m/z 
between 200 and 1500 at a scan rate of 5 sec/scan atomic mass units/second (m/z is the 
molecular mass to charge ratio). Representative spectra were produced by combining the 
scans across the elution peak and subtracting the background. 
2.4 Results and Discussion 
2.4.1 Synthesis 1 of magainin 2 and magainin 2 N 21 
2.4.1.1 Coupling of the first amino acid 
The first amino acid (Ser23) is attached to the resin with an ester bond3. The PyBOp® method 
(section 2.4.3.2), with Fmoc-L-Ser(tBu)-Odhbt as active amino acid derivative, was used for 
this coupling. The initial coupling was evaluated after four and eight hours using the Fmoc-
test (section 2.4.3.5). After four hours, 55% coupling was obtained, while after eight hours, 
72% coupling was obtained. The coupling mixture was then removed and replaced with fresh 
mixture and allowed to couple for a further four hours. An evaluation of the coupling showed 
85% coupling of serine to the resin, which was confirmed with amino acid analysis (results 
not shown). Further attempts at increasing the percentage coupling failed and it was assumed 
that the resin had a 0.17 milli-equivalents/gram resin. 
2.4.1.2 Elongation of the peptide chain 
Following the initial coupling of Ser23 to the resin, the next amino acid in the sequence to be 
coupled was ASP22. After coupling for 60 minutes the Kaiser test was still positive, which 
implied that coupling was not yet complete. Amino acid analysis showed that only 62% 
coupling had taken place. The coupling reaction was repeated and allowed to proceed for four 
hours. The Kaiser test, however, remained positive, and amino acid analysis showed that no 
further coupling had taken place. At this stage we thought that owing to the prolonged 
3 Coupling the first amino acid is often a difficult process which, unless carried out under controlled conditions, 
can lead to low substitution, racemisation or dipeptide formation [4]. 
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exposure to the coupling mixture, the Fmoc groups protecting the N-terminus of the coupled 
asparagine might have been liberated, and synthesis was therefore continued. Subsequent 
quality control analysis of the Fmoc-L-asparagine-OPfp derivative revealed its degradation. 
TLC analysis showed that the derivative was contaminated with L-asparagine as well as 
" 
breakdown products of the Pfp group. The melting point was also considerably lower than 
expected (132-140°C versus 154-156°C). 
Although the yield from this synthesis was already compromised at this early stage, we 
decided to continue to optimise the synthesis and purification of this peptide. For the rest of 
the synthesis satisfactory Kaiser tests were obtained. After coupling of 21 residues, half of the 
resin was removed for the liberation of the shortened peptide magainin 2 N21 • The full-length 
magainin 2 peptide was synthesised on the remaining resin. Because of the expected low yield 
of full length of peptide (±38% of the peptide product lacked Asn22) from the synthesis at this 
point, we decided to synthesise the shortened peptide magainin 2 N 19 at a later stage. 
After cleavage of the peptides, the yields (dry mass) of the crude freeze-dried peptides were 
not determined because of the large amount of methionine, used as scavenger (section 
2.3.3.6), still present in the samples. Amino acid analysis of the resins after cleavage of the 
peptides showed that all of the peptide had been liberated from the resin (results not shown). 
2.4.1.3 Purification and analysis of peptides products from synthesis 1 
Low molecular mass impurities and the methionine/scavenger mixture were removed from the 
crude peptides using gel-permeation chromatography (Fig. 2.1). The large amount of 
methionine (400 mg at 1 g/50 mL) used in the cleavage mixture, and the limitations imposed 
by the column size (1.5 cm x 25 cm) necessitated numerous chromatography runs per peptide. 
Two major fractions were obtained in the case of each peptide, with the peptide fraction 
eluting first (Ve = 17 mL; Ve is the elution volume) and the methionine containing fraction 
second (Ve= 24 mL). Conservative pooling to ensure the removal of all methionine, as well as 
low percentage coupling values for the first two amino acids, resulted in low yields and 
coupling efficiencies for the two peptides. ESI-MS analysis of the purified peptide products 
confirmed that gel permeation had successfully removed most of the methionine from both 
peptides, however, the deletion peptides lacking Asn22 were present in each of the peptide 
preparations (results not shown). 
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Figure 2.1 An example of the elution profile exhibited by the crude magainin 2 peptide 
when chromatographed on Sephadex G 10. The crude peptide mass was 50 mg. 
Peak A contained the peptide fraction, and peak B the methionine and scavenger 
fraction. 
The peptide products from synthesis 1 were further purified with cation exchange 
chromatography. Identical chromatograms were obtained during the chromatography of the 
magainin 2 and magainin 2 N21 peptide preparations. Three fractions eluted using a linear 
O.OIM to 0.15 M ammonium acetate (PH 6) gradient (results not shown). The ESI-MS 
analysis of the three fractions indicated that no peptide material was present in any of the 
peaks (results not shown). Subsequent regeneration of the column with 0.5M ammonium 
acetate eluted both peptides showing that the cationic nature of both peptides had been largely 
underestimated. The optimal gradient for the purification of these cationic peptides was found 
to be a linear gradient starting with 0.35M ammonium acetate (PH 6) as the equilibration 
buffer and ending with 0.45M ammonium acetate (PH 6) as the final concentration (Fig. 2.2). 
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Figure 2.2 CM Sepharose CL-6B cation exchange chromatography of the retained peptide 
preparations of magainin 2 and magainin 2 N21, and the deletion peptides 
magainin 2 and magainin 2 N21 , each lacking Asn22 • Fraction A represents 
magainin 2 and the deletion peptide lacking Asn22• Fraction B represents 
magainin 2 N21 and the deletion peptide lacking Asn22 • 
With this gradient it was possible to separate the peptide mixture eluted from the column 
during regeneration; however, it was impossible to remove the deletion peptides, which were 
retained with their full-length counterparts. In Fig.2.3 the ESI-MS spectra of the two peptide 
preparations (fractions A and B in Fig 2.2) are shown. TLC of the peptides together with the 
deletion peptides showed single ninhydrin-positive components with identical Rr values 
(Rr=0.68), confirming the similarity of all four peptides (results not shown). The final option 
in purifying the peptides would have been HPLC, but because of the product loss during the 
repetitive purification steps, the final yields for both peptides were very low. We therefore 
decided to re-synthesise the peptide using the experience gained from this first synthesis. 
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Figure 2.3 Positive mode ESI-MS of fraction A and B collected after CM Sepharose CL-6B 
cation exchange chromatography of the peptide mixture. Fraction A contains the 
following peptides: A representing magainin 2, and Ai representing magainin 2 
excluding asparigine 22. Fraction B contains the following peptides: B 
representing magainin 2 N 21 , and Bi representing magainin 2 N 2 i excluding 
asparigine 22. Fraction B showed minor contamination with peptide Ai. 
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2.4.2 Synthesis 2 of magainin 2, magainin 2 N 2J, and magainin 2 N J9 
2.4.2.1 Coupling of the first amino acid 
Pure Fmoc-L-Asn-Opfp was synthesised (section 2.3.2.4) and stringent quality control tests 
were performed on the other derivatives. Fmoc-Gly-Opfp did not pass quality control testing 
and was re-crystallised as described in section 2.3.2.3. The PYBOp® method, with another 
Ser-derivative, Fmoc-L-Ser(tBu)-OH, was again used to couple Ser23 to the resin. After an 
initial four-hour coupling period the Fmoc test showed the resin to be 74% saturated. After a 
second two-hour coupling the Fmoc test showed the resin to be 100% saturated with the first 
Fmoc amino acid. This indicated that the initial assumption of the resin capacity being 
0.17 milli-equivalentlgram was incorrect. The successful coupling was attributed to the use of 
Fmoc-L-Ser(tBu)-OH in place of the Fmoc-L-Ser(tBu)-Odhbt derivative: 
2.4.2.2 Elongation of the peptide chain 
Satisfactory Kaiser tests were obtained for each of the next 22 .~oupling/deblocking steps. 
After coupling 19 residues, a third of the resin was removed for the liberation of the deletion 
analogue, magainin 2 N 19• Two more amino acids wer~ coupled:to the rest' of the resin, and 
half was removed for the liberation of the deletion analogue, magainin 2 N21 • The last two 
;} 
N-terminal amino acids were coupled to the rest of the resin for the liberation of the 
full-length peptide. Peptides were cleaved from the resin as described under section 2.3.3.6. 
Amino acid analysis of resins samples after cleavage showed that all peptide material was 
successfully liberated (results not shown). 
2.4.2.3 Purification of peptides 
Initial analytical HPLC of th~ crude peptides (results not shown) showed the presence of some 
impurities in all three peptide preparations. The peptides were subsequently chromatographed 
on Sephadex G 10 (Fig. 2.4). A larger column was used (45 cm x 1.5 cm) for this purification 
step, making it possible to increase the concentration of peptide loaded onto the column, while 
still retaining suitable resolution. For all three peptide preparations, a single major absorbing 
fraction was obtained which eluted between 33 and 35 mL. 
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Figure 2.4 Examples of the elution profiles exhibited by the crude peptide preparations of 
magainin 2 and deletion analogues when chromatographed on Sephadex G 10. 
Each of the crude peptides was chromatographed in two separate runs with the 
dry peptide masses ranging from 30-40 mg per run. 
Taking into account chromatographic losses as a result of conservative pooling of fractions 
and possible interaction between the peptides and the plastic tubing of the chromatographic 
set-up, peptide yields and coupling efficiencies were calculated for each peptide (Table 2.4). 
From analytical HPLC of the Sephadex G 10 chromatographed peptides it was calculated4 that 
magainin 2 N 19 was 73% pure, magainin 2 N21 was 84% pure and magainin 2 was 60% pure 
(results not shown). 
To obtain peptides at a purity of >96%, the three peptides were subsequently purified using 
semi-preparative HPLC. Fractions were collected as shown in Fig. 2.5. Peptide yields are 
listed in Table 2.4. 
4 % Purity = area of peptide peak / total area peaks x lOO. 
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Table 2.4 A summary of the yields obtained for the synthesis and purification of magainin 
2 and the N-terminal deletion peptides. Yields were determined on the dry mass 
of each peptide. 
Peptide % Crude yield a 0/0 Average coupling 0/0 Yield from 
efficiency b preparative 
HPLC c 
magainin 2 53 97 53 
magainin 2 N21 52 97 62 
magainin 2 N 19 53 97 55 
a % Crude yield = mass peptide obtained / mass peptide expected x 100 
b % Coupling efficiency = Yield lin X 100 (n = number of amino acids in peptide) 
C % HPLC yield = mass HPLC injected peptide / mass purified peptide x 100 
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Figure 2.5 Semi-preparative HPLC chromatograms of the peptide preparations. Peak 
fractions collected are indicated by the dashed lines. The linear gradient was 
developed over 13 minutes with 0.1 % TF A in water as solvent A and 
acetonitrile plus 10% A as solvent B at a flow rate of 3 mLimin. 
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2.4.3 Analysis ofpurified pep tides 
2.4.3.1 Analytical HPLC of the purified peptides 
Analytical HPLC was used to assess the semi-preparative purification of the peptides. All 
three peptides were of a purity >96%4 (Fig. 2.6). 
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Figure 2.6 Analytical HPLC chromatograms of the purified peptide products from synthesis 
2. The linear gradient was developed over 13 minutes with 0.1 % TF A in water as 
solvent A and acetonitrile plus 10% A as solvent B at a flow rate of 1 mL/min 
Each of the pep tides exhibited slight aggregation as shown by the small peak: eluting at the 
void volume of 1.4 mL. The two deletion analogues showed almost no difference with regard 
to their retention on the C I8 HPLC matrix. The slight increase in retention (possibly also 
hydrophobicity) of magainin 2 N21 was attributed to its extra glycine residue. The full-length 
magainin 2 had a retention time ±30 seconds greater than its deletion analogues. Its increased 
retention and hydrophobicity was attributed to the extra two glycine residues and isoleucine 
residue in its peptide sequence. 
2.4.3.2 Electrospray ionisation mass spectrometry of the purified peptides 
The correct mlz (molecular mass/charge ratio) was found for each of the peptides, and all three 
peptides were shown to be pure. Spectra of magainin 2 (Fig.2.7) indicated the correct mlz in 
mUltiply charged forms, namely 494.5 ([M+5Hf+), 617.9 ([M+4H]4+), 823.3 ([M+3H]3+), and 
1234.3 ([M+2H]2+). Na and K cationised species were also observed in the triply and quadruply 
charged forms of the peptide. The quadruply (mlz = 613.6) and quintuply (mlz = 491.1) charged 
species differing by 17 Da, indicate the loss of an OH group. 
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The magainin 2 N21 spectrum (Fig 2.7) showed the correct mlz in mUltiply charged forms, 
namely 575.3 ([M+4Ht+), 766.6 ([M+ 3H]3+), and 1149.3 ([M+2Hf+). The quadruply charged 
specie differing by 17 Da from the molecular ion was again observed (mlz = 570.9). 
Magainin 2 N l9 also showed the correct mlz in multiply charged forms (Fig.2.7), namely 528.9 
([M+4Hr), 704.9 ([M+3Hr), and 1056.6 ([M+2Hr). A triply charged acetonitrile adduct 
(rn/z = 718.8), a quadruply charged specie differing by 17 Da (rn/z = 524.5), and a quadruply 
charged K+ cationised speCIe (rn/z = 538.5) were also observed in the spectra of the 
19-residue peptide. 
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Figure 2.7 Positive mode ESI-MS spectra of the purified magainin 2 peptide and the two 
N-terminal deletion peptides, magainin 2 N 21 and magainin 2 N 19• Analyses were 
performed as described under section 2.3.5.4. 
2.5 Conclusions 
The Fmoc-polyamide protocol proved to be successful in the synthesis of magainin 2 and the 
two shortened peptides. Experience gained during the first synthesis of these peptides helped 
to ensure the high yields and high purity peptide products obtained in the second synthesis. 
The necessity for quality control checks on all derivatives, even newly acquired ones, prior to 
synthesis was found to be essential to ensure a successful synthesis. There are numerous 
reasons for the degradation of derivatives, of which the most prevalent are storage conditions 
(for example temperature, moisture, light, volatile organic and inorganic contamination of 
reagents) and it is recommended that the purity of derivatives be checked regularly [17]. 
Coupling of the first amino acid was also noted to be a critical step in the synthesis. In 
synthesis 1, the derivative Fmoc-L-Ser(tBu)-Odhbt was used for this step, and only 85% 
saturation of the resin could be obtained. This indicated that that the PyBOp® method was not 
suitable for coupling a derivative containing an Odhbt ester. Furthermore, the attempted 
coupling of the degraded Fmoc-L-Asn-OPfp derivative resulted in the formation of the two 
deletion peptides, which, owing to their similarity with the full length peptides, proved to be 
difficult to remove. This showed the importance of maximum coupling, and what effect 
sub-standard couplings have on yields and subsequent purification steps. Further 
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complications arose when the peptides were retained on the column during the cation 
exchange purification step, resulting in an undesired mixture of the peptides. This emphasised 
the extreme cationic nature of the peptides, and a new gradient was developed which was able 
to separate and partly purify the peptides. 
For the second synthesis Fmoc-L-Ser(tBu)-OH was used for the initial coupling step, and 
maximum coupling was achieved. Pure Fmoc-L-Asn-OPfp was synthesised (section 2.3.2.4) 
for the second coupling step, and this too coupled successfully as shown by a negative Kaiser 
test. Further quality control checks were done on the other derivatives prior to coupling; and 
the second synthesis proceeded without complication. The use of reagent K [22] to cleave the 
peptide from the resin decreased the number of purification steps, as it was unnecessary to use 
methionine as a scavenger. Peptides were purified to purity of >96% using reverse phase 
HPLC, and subsequent ESI-MS analysis confirmed the purity of the peptides. ESI-MS 
analysis showed the pure peptides in their multiply charged forms with no evidence of any 
contaminants. 
Finally, the peptide products were of sufficient purity for use . in biological activity 
experiments. In Chapter 3, I shall report on the development and evaluation of an 
antimicrobial assay to test these peptides, and in Chapter 4 the capability of magainin 2 and its 
analogues to render tetracycline resistant E. coli susceptible to tetracycline shall be examined. 
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Chapter 3 
A sensitive standardised micro-gell well diffusion assay for 
the'determination of antimicrobial activity 1 
3.1 Introduction 
With the discovery of antibiotics and vast numbers of antimicrobial peptides, numerous 
methods have been developed to test these compounds against various organisms. In the 
beginning, for lack of alternatives, bacteria were incubated with these compounds and the 
rate of decrease in viable counts monitored. This, however, was found to be too time and 
material consuming, and new, more efficient methods were sought. 
A number of methods were since developed with the emphasis on the conservation of test 
material. The earliest, most successful methods simply entailed the formation of i~ibition 
zones by an antibiotic in a lawn of bacteria growing in agar [1]. The inhibition zones were 
physically measured to determine the antimicr?bial activity of the antibiotic. For ,example, 
the agar cup assay method for determining the activity of penicillin was developed as far 
back as 1946 [2]. Researchers favoured these methods because they required very little test 
material and could be carried out relatively easily. Later, however, agar was found to be 
unsuitable for testing certain antimicrobial molecules, as it contained specific extrinsic 
substances or contaminants that hampered the diffusion of these molecules. This led to 
agar being replaced by a high quality agarose in many of the assays [3]. 
To date the microtiter plate has played an integral role in the development of various 
micro-assays, with one of the most well-known being the enzyme-linked immunosorbent 
assay (ELISA) [4]. Literally hundreds of assays are now performed in microtiter plates, 
I In collaboration with M, Rautenbach to be submitted to J Microbial. Methods 
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because 96 wells can be used per experiment, small amounts of test material are required, 
and results can easily be quantitated spectrophotometrically using a microtiter plate reader. 
We developed a highly sensitive micro-gel well diffusion assay by adapting an inhibition 
zone assay to perform it in a microtiter plate. Hereafter, our method is compared to an 
inhibition zone assay and a microtiter broth dilution method. Gramicidin S (an antibiotic 
cycIodecapeptide from Bacillus brevis) was used as the model antbibiotic and Micrococcus 
lute us (a Gram-positive bacterium) as the indicator organism. 
3.2 Materials 
M lute us (NCTC 8340) was used as indicator organism in all experiments. Dr. R. Levitt, 
Fine Chemicals, South Africa, donated synthetic gramicidin S. Microtiter plates (Nunc-
Immuno™ Maxisorp) were from Nalge NUNC International (Roskilde, Denmark), Falcon® 
tubes from Becton Dickinson Labware (Lincoln Park, USA), and culture dishes from 
Quality Scientific Plastics, USA. Low-electroendosmosis-type agarose (DI-LE) was from 
Whitehead Scientific (Brackenfell, South Africa). Tween 20 and Coomassie brilliant blue 
R-250 were from from Fluka (Buchs, Switzerland). Dulbecco's phosphate buffered saline 
(PBS) was either from Life Technologies (Faisley, Scotland), or prepared in the laboratory 
[5]. Sodium chloride and glacial acetic acid were from Saarchem (Krugersdorp, South 
Africa). Disodium hydrogen phosphate, methanol (99%), potassium chloride, potassium 
dihydrogen phosphate, tryptone soy broth (TSB), dimethylsulphoxide (DMSO), casein, 
and formaldehyde (99%) were from Merck (Darmstadt, Germany). Bovine serum albumin 
(BSA) was from Boehringer Mannheim (Germany). Analytical quality water was prepared 
by filtering glass distilled water through a Millipore Milli Q® water purification system. 
3.3 Methods 
3.3.1 Preparation of cells 
3.3.1.1 Radial diffusion assay (RDA) and the micro-gel well diffusion assay 
Bacteria were grown overnight at 37°C in TSB, sub-cultured and grown to an optical 
density (OD) of 0.6 at 620 nm. The cells were centrifuged for 10 minutes at 900 g. The 
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supernatant was discarded and the cells were washed once with 10 mL cold Oulbecco's 
PBS by centrifugation. Finally, the cells were diluted to an 00 of 0.6 in Oulbecco's PBS 
[6]. 
3.3.1.2 Microtiter broth dilution method 
Bacteria were grown overnight at 37°C in TSB, sub-cultured and grown to an 00 of 0.6 at 
620 nm. The cells were diluted with TSB to 5xl05 colony forming units per mL (CFU/mL) 
based on the relationship 00620 0.20=5x105 CFU/mL [6]. 
3.3.2 Radial diffusion assay 
The radial diffusion assay was adapted from the method of Lehrer et al. [6]. A gel solution 
containing 1 % (w/v) of powdered TSB medium, 1 % (w/v) of low-electroendosmosis-type 
agarose, and 0.02% (v/v) Tween 20 made up in Oulbecco's PBS was prepared and 
autoclaved. Culture dishes were blocked with 0.5% casein in Oulbecco's PBS for one hour 
and dried under ultraviolet light for a further four hours. Ten mL of the gel, at 45°C, was 
aliquoted and added to 1 mL of the dilute bacterial culture and dispersed for ten seconds 
using a laboratory vortex. Once the bacteria were adequately dispersed, the gel was poured 
into a circular culture dish on a level platform. The gel was then allowed to set for one 
hour, before wells were made using a 5 mm punch. The test sample was dissolved in 
analytical quality water and then further diluted (doubling serial dilutions). After adding 15 
/-lL of sample material to each well, the plates were incubated for three hours at 37°C and 
then turned over and incubated for a further 14 hours at 37°C. The gel was stained for 24 
hours in a dilute solution of Coomassie brilliant blue R-250 (2 mg dye; 27 mL methanol; 
63 mL water and 15 mL 37% formaldehyde). The spent staining solution was decanted, 
replaced with an aqueous solution of 10% acetic acid and 2% OMSO and left for 
approximately ten minutes. The areas of the clear zones surrounding the wells were 
calculated from calliper measurements of a 190% enlarged photocopy of the stained gels. 
The gels were stored in water at 4°C. 
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3.3.3 Microtiter Broth Dilution Method 
The microtiter broth dilution method, microbroth dilution assay, and versions of it have 
previously been described [7, 8, 9]. The test sample was dissolved in analytical quality 
water at twice the required maximal concentration, and then diluted 1: 1 with 0.02% acetic 
acid, 0.4% bovine serum albumin (BSA) to the required stock concentration. Further 
doubling serial dilutions were made using 0.01 % acetic acid, 0.2% BSA. TSB (100 ilL) 
was pipetted into each of the wells of the first column of the microtiter plate as a sterility 
control and blank. The rest of the wells each received 100 ilL of the bacterial suspension. 
A volume of 30 ilL of the test sample was pipetted into all wells excluding the first two 
rows that served as growth controls. The plate was covered and incubated at 37°C for 
17 hours and the light dispersion in each well determined using a microtiter plate reader 
(Multiscan Titertek) at 620 nm. 
3.3.4 Micro-gel well diffusion assay 
Microtiter plates were blocked with 0.5% casein in Dulbecco's PBS for one hour and 
sterilised under ultraviolet light for a furth~r four hours. The gel was prepared as in the 
radial diffusion assay and kept in a water bath at 46 ±1°C. The following modified 
pipetting technique was essential for obtaining reproducible results: 7,0 ilL of the heated 
gel suspension was drawn up, using a Gilson® micropipette, by depressing the pipette 
plunger to its maximum, and pipetted by depressing the plunger only as far as its first 
stoppage point. The normal method of pipetting was therefore reversed t~ prevent bubble 
formation. The first column of the micro titer plate received only 70 ilL of gel, to serve as 
blank and sterility control. The other wells each received 70 ilL of a bacterial-gel 
. ..' ., 
"",' .. 
suspension (70 ilL bacteria and 700 ilL gel dispersed with a laboratory vortex). The 
suspension were prepared for each column immediately before application. Once the 
desired number of wells were prepared, the gel was allowed to set for 30 minutes. The test 
sample was 'dissolved in analytical grade water and then further diluted (doubling serial 
dilutions). After applying 30 ilL of sample directly onto the gel in the wells the microtiter 
plate was covered and incubated for 17 hours at 37°C. The light dispersion per well was 
determined using a Multiscan Titertek microtiter plate reader at 620 nm. The plates were 
preserved by adding 140 ilL of a solution containing 27 mL methanol, 63 mL water and 15 
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formaldehyde to each well. The gel was stained by adding 100 /J.L of a 0.002% solution of 
Coomassie brilliant blue R-250. After 24 hours the colouring solution was discarded and 
replaced by water before storage at 4°C. 
3.3.5 Data processing 
All data was analysed using, Graphpad Prism verSlOn 2.01 for Windows, GraphPad 
Software, San Diego, California, USA (www.graphpad.com). 
Nonlinear regression was performed on the dose-response data and a sigmoidal curve with 
variable slope was fitted to each of the data sets. The 50% inhibition of microbial growth 
(ICso), the minimum inhibitory concentration (MIC), and the maximum bactericidal 
concentration (MBC) values were deduced as shown in the example in Fig. 3.1. 
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Figure 3.1 A typical sigmoidal dose-response curve obtained with data analysis using 
Graphpad Prism 2.01 software. A represents the MIC value, B the ICso, and C 
theMBC. 
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The equation used for the sigmoidal curve with variable slope was: 
Y = Bottom + (Top - Bottom)/(1 + 10 IOQICsoxHiIlSIOpe) where: 
Bottom = Y -value at the bottom plateau 
Top = Y-value at top plateau 
log leso = X-value of response halfway between top and bottom 
Hill slope = Hill coefficient or slope factor (determines steepness of curve) 
A statistical analysis of the results was done using the statistical functions of the Prism 
software. MIC values, obtained from all three methods, were analysed doing a one-way 
analysis of variance (one-way ANOV A). MBC and IC50 values obtained from the micro titer 
broth dilution method and the micro-gel well diffusion method were analysed statistically 
using the unpaired t-test. 
3.4 Results and Discussion 
We found that all three methods were compatible with the model antibiotic, gramicidin S, 
and with the indicator organism, M luteus. The three methods are compared in Table 3.l. 
Experiments using RDA provided highly visual results. Sharply defined zones of clearing 
could be observed as a consequence of the growth inhibition of M luteus by various 
concentrations of gramicidin S. The inhibition zone areas were found to be directly 
proportional (r2=0.99) to the concentration of gramicidin S over a concentration range from 
5 to 120 flg/mL (Fig. 3.2). For a concentration of 3.0 flg/mL and less, no inhibition zones 
were observed (Fig. 3.2). From these results we obtained a MIC value of 5.3 ±0.1 flg/mL 
for gramicidin S. 
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Table 3.1 A comparison of the protocols for the RDA, micro-gel well diffusion assay, 
and microtiter broth dilution method. 
Radial diffusion Micro-gel well Microtiter broth 
assay diffusion assay dilution method 
Experimental Petri dish Microtiter plate Microtiter plate 
container 
Prevention of Coated with casein Coated with Sample in 0.01 % 
peptide-plastic buffer casein buffer acetic acid, 0.2% 
interaction BSA 
Growth medium Low-endosmosis Low-endosmosis Tryptone soy broth 
type agarose + type agarose + 
TSB TSB 
Cell count 1.4x107 CFU/mL 7.5x105 CFU/mL 5x105 CFU/mL 
Incubation time 17 hours 17 hours 17 hours 
Measurement 2x enlargement of Light dispersion Light dispersion at 
method inhibition zones at 620nm 620nm 
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Figure 3.2 An example of a dose-response curve from a RDA experiment. The solid line 
indicates a linear response (r2 = 0.99) over the concentration range: 5 to 120 
!J.g/mL. The MIC value shown on the graph is 5.4 !J.g/mL. The error bars 
represent the SEMs (quadruplicate determinations). 
Sigmoidal dose-responses curves were obtained after analysis of the results from the 
microtiter broth dilution method and the micro-gel well diffusion assay. From these curves 
the MIC, MBC, and ICso values were deduced (Figs. 3.3 and 3.4, Table 3.2). 
A comparison of the MIC values from the two types of microtiter-based assays showed 
them to be approximately twice as sensitive as the RDA (2.3 and 2.0 !J.g/mL vs. 
5.3 !J.g/mL). Furthermore, all three MIC values were significantly different (P<O.OOI). The 
MBC and ICso values from the micro-gel well diffusion assay and microtiter broth dilution 
method were also significantly different, with P<0.05. 
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Table 3.2. MIC, MBC, and IC50 values of gramicidin S against M lute us. Three 
independent experiments were performed per method and each concentration 
per experiment was determined in quadruplicate. 
Method MIC (llg/mLy ,2 I Cso (llg/mL) 1, 3 MBC (llg/mLY ·3 
Micro-gel well 
diffusion assay 2.3 ± 0.1 3.4 ± 0.1 4,8 ± 0.2 
Microtiter broth 
dilution method 1.9 ± 0.1 2.2 ± 0.1 2.6 ± 0.1 
Radial diffusion 
assay 5.3 ± 0.1 NA NA 
Values are means ± standard error of the mean (SEM) 
2 MIC values from all three methods differed significantly from each other (p<O.OOI) 
3 MBC and ICso values from the microtiter broth dilution method and micro-gel well 
diffusion assay were significantly different (p<O.05). 
~ 
~ 
::J 
-
=: 
:6 
50 
~ 40 
e 
C) 30 
~ 0 
20 
10 
0 
-10 
-0.25 -0.05 0.15 1.55 1.75 1.95 
log gramicidin 5 (llg/mL) 
Figure 3.3 An example of a sigmoidal dose-response curve from a microtiter broth 
dilution method experiment. A represents the MIC value (1.6 Ilg/mL), B the 
IC50 value (2.2 Ilg/mL), and C the MBC value (2.7 Ilg/mL). The error bars 
represent the SEMs (quadruplicate determinations). 
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Figure 3.4 An example of a sigmoidal dose-response curve from a micro-gel well 
diffusion assay experiment. A represents the MIC value (2.3 ~g/mL), B the 
ICso value (3.2 I-lg/mL), and C the MBC value (4.3 I-lg/mL). The error bars 
represent the SEMs (quadruplicate determinations). 
Staining the gel in the micro-gel well diffusion method notably enhanced the visible 
inhibition in each well. This created an excellent visual record of the result (Fig. 3.5). We 
found, however, that staining did not enhance the sensitivity, and we therefore recommend 
that this be done after the plate has been scanned on the microtiter plate reader. 
Comparison of the RDA and micro-gel well diffusion assay showed that blocking the plate 
with casein did not affect the ICso values, and that sterility was also not compromised 
(results not shown). Even though the ICso value remained unchanged with gramicidin S as 
test compound, this might not be the case for all antimicrobial compounds, therefore this 
blocking step is recommended. 
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Figure 3.5 A photograph of a micro-gel well diffusion assay experiment after fixation and 
colouring. Column one contains only gel to serve as a blank: and sterility 
control. Rows A, G, and H, starting at column two, contain the M luteus-gel 
suspension without gramicidin S. Wells B2 to F2 contain a bacterial-gel 
suspension with gramicidin S (200 JlglmL), from where consecutive columns 
contain doubling dilutions of the peptide. The final column (wells B12 to F12) 
contains the lowest gramicidin S concentration (0.2 JlglmL). 
3.5 Conclusions 
In general, all three methods investigated here were easily manageable and highly repeatable 
results were obtained. There are, however, some advantages and disadvantages to each of 
them. The use of a microtiter plate allows for a much larger and more economical 
experiment, as opposed to a culture dish which can accommodate far fewer wells per dish. 
Furthermore, determining inhibition by a spectrophotometric method, using a microtiter 
plate reader, is more sensitive and accurate than physically measuring zones of inhibition, 
because of possible human bias in measuring. Comparing the microtiter broth dilution 
method and the micro-gel well diffusion assay, it is clear that the microtiter broth dilution 
method is the less labour intensive of the two, and is therefore ideal for screening large 
numbers of test samples. The use of a liquid broth as growth medium also allows for almost 
immediate antibiotic-cell interaction, as opposed to agar or agarose where it depends on 
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diffusion rate. Agar or agarose, on the other hand, is advantageous in that microbial 
heterogeneity or contamination can be detected readily by observing the nature of bacterial 
growth, as opposed to a broth where a contamination would not be directly discovered [1]. 
Results from the agarose-based assays were also easily manipulated through the use of 
fixing agents and staining agents. By using a fixing agent it is possible to halt the 
experiment at any specific time, as well as to preserve the experiment for an undetermined 
period oftime. By using a staining agent it is possible to create a visual record of the result. 
The RDA gave a good indication of antimicrobial activity through the formation of 
inhibition zones. This method, however, was not as sensitive as the other two. No 
inhibition zones were visible at gramicidin S concentrations < 3.0 j..lg/mL. This result could 
possibly be attributed to the fact that, at very low concentrations, the test sample might not 
diffuse far enough into the gel to form a visible inhibition zone. The micro-gel well 
diffusion assay, in contrast, only depends upon the localised downward diffusion of the test 
sample. Because the reaction area is not as large as that of the RDA, diffusion of molecules 
of varying molecular size is also no longer a limiting factor. 
In other experiments we demonstrated the versatility of the micro-gel well diffusion assay 
by using various other antimicrobial compounds, as well as Escherichia coli as Gram-
negative indicator organism. Antimicrobial compounds assayed included the cationic frog 
peptide, magainin 2 and some N-terminal deletion analogues, cationic model peptides from 
a combinatorial library, and the antibiotic tetracycline (see Chapter 4). 
Generally, there is some difficulty in standardising antimicrobial assays because there is no 
single assay is compatible with all antimicrobial compounds. It seems therefore that 
researchers will have to decide upon, and make use of a method best suited to their work. 
The statistical analysis of the results from the three methods, shows that all three sets of 
results differed significantly from each another. This emphasises the fact that if identical 
assays are not used, results .cannot be compared. The micro-gel well diffusion assay and 
our method of data analysis, using Prism software, improved the sensitivity of the current 
agar or agarose-based assays. 
In the following chapter the micro-gel well diffusion assay shall be used to test the 
susceptibility of antibiotic resistant organisms to a combination of antibiotics and 
antimicrobial peptides. 
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Chapter 4 
The synergistic antimicrobial effect of tetracycline and 
magainin 2, and N-terminal deletion analogues, on 
tetracycline resistant Escherichia coli 
4.1 Introduction 
4.1 
Antibiotics are one of the most important therapeutic discoveries in medicine, but their 
benefits are rapidly being lost as a consequence of an ever-increasing rise in antibiotic 
resistance. This problem has become global, and holds significant implications for future 
health and patient care [1]. With the recent emergence of vancomycin insensitive 
Staphylococcus aureus it is clear that steps must be taken to curb the rise in resistant bacteria 
[2]. 
Bacteria make use of inventive and versatile mechanisms to resist antibiotics and other toxic 
elements. These mechanisms can either be specific or general in their mode of action. 
Examples of specific mechanisms of resistance include drug-inactivating enzymes [3] (e.g. 
beta-Iactamases which destroy the beta-Iactam ring of penicillin and cephalosporins), drug 
modifications [3] (eg. aminoglycoside and macrolide resistance), mutations in the antibiotic 
target site itself [3] (eg. the RNA polymerase for rifampicin), and acquisition of genes 
encoding antibiotic target proteins which are insensitive to the antibiotic [3]. The more 
_ general mechanisms include, for example, an organism surrounding itself with a barrier of low 
permeability or expelling the drug by means of an energy dependent pump [4]. Of the more 
general mechanisms, active efflux systems are responsible for resistance to a variety of 
structurally unrelated antibiotics, and are being recognised more frequently in increasing 
numbers of environmental and clinical isolates [4]. Antibiotics are extruded by an energy-
dependent process linked to the proton-motive force [4]. The existence of multi drug efflux 
systems indicates that this form of resistance has become non-specific in nature, signifying the 
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development of bacteria resistant to numerous antibiotics [4]. (Refer to Chapter for more 
detail) 
We used an antimicrobial peptide in conjunction with a conventional antibiotic, on bacteria 
resistant to the antibiotic in an attempt to overcome the resistance. The mechanism of 
resistance targeted was the energy dependent efflux pumps .. In developing a model system, 
tetracycline was chosen as antibiotic (FigA.l), Escherichia coli JM 1 09 as the tetracycline 
resistant organism, and magainin 2, as well as two N-terminal deletion analogues, as the 
antimicrobial peptides. 
Tetracycline curbs bacterial growth by inhibiting aminoacyl transfer RNA binding. It binds to 
both the 30S and 70S ribosomal subunits, and inhibits the binding of aminoacyl transfer 
RNAs (tRNAs) at the so-called A site [5]. 
OH 
~~H N 
OH 0 OH 0 o 
Figure. 4. 1 Structural formula of tetracycline. 
Magainin 2, a linear cationic peptide originally isolated from the African clawed frog Xenopus 
laevis, forms ion permeable channels in cell membranes which ultimately leads to cell death 
(see. section 1.6.3). We therefore set out to determine whether the permeabilisation effect of 
magainin 2 on the bacterial outer membrane could perhaps facilitate the entry of tetracycline 
into the cell to such a degree that the active efflux pumps would be neutralised, thus reducing 
the degree of resistance (Fig. 4.2). 
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Figure 4.2 A diagram illustrating our proposed strategy to overcome the active efflux 
pumps that certain bacteria utilise as a mechanism of resistance. A shows how 
resistant bacteria pump the antibiotic out of the cell before it can reach its target. 
B shows how we intend to make use of an antimicrobial peptide to disrupt the 
bacterial membranes making them more permeable to the antibiotic [6]. 
4.2 Materials 
E. coli strains, JMI09 (containing the ~-lactamase encoding plasmid, pBR322) and HBIOI 
were used in all experiments. Tetracycline was from Sigma-Aldrich (St. Louis, Missouri, 
USA). Analytical quality water was prepared by filtering glass distilled water through a 
Millipore Milli Q® water purification system. HV 0.45 micron membrane filters were from 
Waters-Millipore (Milford, USA). Ethanol (99.8%) was from Merck (Darmstadt, Germany). 
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4.3 Methods 
4.3.1 Peptide synthesis and purification 
Peptides were synthesised at room temperature (20-25°C) according to the Fmoc-polyamide 
" 
protocol using the shake flask bench procedure (see Chapter 2, section 2.3.3. Crude peptides 
were purified to >96% homogeneity as described in Chapter 2. 
4.3.2 Antimicrobial assay 
Peptides were filtered through HV 0.45 11m Millipore filters on the day before performing an 
experiment to remove any insoluble particles, and then freeze-dried overnight. Tetracycline 
dilutions were made from a standardised stock solution (5 mg/mL in 70% ethanol), which was 
used for no longer than one week, as the tetracycline tended to precipitate if kept for longer. 
, 
Stock solutions were kept in amber vials at -10°C. Peptide dilutions were made from a 
1 mg/mL stock solution (in analytical grade water), prepared directly before performing an 
assay. 
For all antimicrobial determinations we used the micro-gel well dispersion assay (see Chapter 
3). When performing an assay for synergism or combined inhibition studies, six dilutions of 
tetracycline were prepared, each inhibiting the growth of E. coli at a specific point over an 
evenly spread range of 0 to 100% bacterial growth. Tetracycline and peptide dilutions 
(minimum inhibitory concentrations, MIC, and the concentration resulting in 50% inhibition 
of microbial growth, IC5o), were prepared at twice their required concentrations. Equal 
volumes (15 ilL) of peptide and tetracycline were added to the desired wells, which resulted in 
a 1: 1 dilution of the respective antimicrobial compounds. 
For the determination of synergism, three separate controls were used to calculate bacterial 
growth (analytical grade water controls (30 ilL), peptide at its MIC (15 ilL) and water (15 ilL) 
controls, and peptide at its IC50 (15 ilL) and water (15 ilL) controls). Bacterial inhibition of 
those wells, that received tetracycline and water, was calculated in terms of growth in control 
wells containing water. These wells showed the effect of tetracycline alone, and IC50 values 
obtained could be compared to previously obtained IC50 values, showing the validity of the 
experiment. The bacterial inhibition in wells, that received peptide and tetracycline, was 
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calculated from growth in control wells containing the respective peptide concentration (lCso ' 
or MIC), and water. These calculations facilitated the interpretation of data by ruling out the 
effect of the peptide and helping to identify possible synergism. 
4.3.3 Data processing 
All data was analysed using, Graphpad Prism version 2.01 for Windows, GraphPad Software, 
San Diego, California, USA. 
Nonlinear regression was performed on the dose-response data and a sigmoidal curve with 
variable slope was fitted to each of the data sets (Chapter 3, Fig. 3.1). 
4.3.4 Structure modelling using HyperChem @ 5.0 
Models of the peptide structures were generated with HyperChem® 5.0 [7]. 
4.4- Results and Discussion 
4.4.1 Antimicrobial activities 
Using the micro-gel well dispersion assay, the ICso and MIC values were determined for the 
antibiotic tetracycline against tetracycline resistant (JM109) and non-resistant (HB101) strains 
of E. coli (Table 4.1). The tetracycline resistant strain of E. coli showed an ICso value 
approximately 30 times greater than that of the non-resistant strain. ICso and MIC values for 
the peptides were determined in the same manner (Table 4.1). Magainin 2 was assayed against 
both strains of E. coli, and almost identical ICso and MIC values were obtained in each case. 
Magainin 2 N21 was assayed against the resistant strain of E. coli and the ICso value was 
approximately twice that of magainin 2. Magainin 2 N 19 exhibited no antimicrobial activity 
over the concentration range 9-284 nmoles/mL. Structure modelling of the peptides using 
HyperChem® 5.0 showed how the absence of amino acids from the N-terminal of the peptide 
affected its a-helical structure, and subsequently also its antimicrobial activity. Structure 
modelling of magainin 2 N21 , which lacked a glycine and isoleucine residue, showed the 
definite formation of a cavity in the hydrophobic face of the amphipathic a-helix of the 
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peptide (Fig 4.3 i). Further modelling of magainin 2 N 19, which lacked additional glycine and 
lysine residues, showed the formation of a second cavity in the hydrophilic face of the 
amphipathic a-helix of the peptide (Fig. 4.3 ii). 
Table 4.1. MIC and ICso values of tetracycline, magainin 2, magainin 2 N2I , and magainin 2 
N I9 against E. coli. Magainin 2 was assayed against both strains of E. coli. Two 
independent experiments were performed per value and each concentration per 
experiment was determined in quadruplicate. 
MIC (nmol/mL)1 ICso(nmol/mL)' 
Tetracycline against non-resistant E. coli HBIOI (n=2) 0.2 ± 0.007 1.4 ± 0.005 
Tetracycline against resistant E. coli JMI09 (n=2) 
14.4±1.1 44.1 ± 0.5 
Magainin 2 against E. coli HBIOI 8.7 29.7 
Magainin 2 against E. coli JMI09 (n=2) 8.4 ± 1.2 29.0 ± 0.9 
Magainin 2 N2l against E. coli JMI09 (n=2) 23.6 ± 0.3 63.6 ± 0.4 
Magainin 2 Nl9 against E. coli JMI09 (n=2) 
> 284 > 284 
I Values are means ± SEM 
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Figure 4.3 Peptide structures modelled using HyperChem 5.0® showing the a-helical 
conformations of the peptides as viewed from the top (N-terminal at the top) . 
The dark blue lines depict the nitrogen, red the oxygen, light blue the carbon, 
yellow the sulpher and green the hydrogen atoms. A represents magainin 2 N19, 
with i and ii indicating the cavities formed in the hydrophobic and hydrophilic 
face of the amphipathic a-helix as a result of the omission of the four residues 
from the N-terrninal of the peptide. B represents magainin 2 N21, with ii 
indicating the cavity formed in the hydrophobic face of the amphipathic a helix as 
a result of the omission of two residues from the N-terminal of the peptide. C 
represents magainin 2. 
4.4.2 Determination of synergism between the antimicrobial peptides and 
tetracycline on tetracycline resistant E. coli 
Sigmoidal dose-response curves for tetracycline and magainin 2 (at its IC50 and MIC) and 
tetracycline are shown in Fig. 4.4A. For tetracycline concentrations above its MIC there was 
no synergism, while at concentrations below its MIC there was significant synergism between 
the peptide and tetracycline. Magainin 2 at its MIC, and tetracycline concentrations below its 
MIC synergistically inhibited the growth of E. coli 1Ml09 by ±l2%. Magainin 2 at its IC5o, 
and tetracycline concentrations below its MIC synergistically inhibited the growth of E. coli 
1Ml09 by ±29%. To determine whether this occurrence was as a result of the mechanism of 
resistance, the experiment was repeated on non-resistant E. coli HBlOl. The result, however, 
remained the same (Fig. 4.4B). 
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Identical experiments were performed with magainin 2 N21 and tetracycline on E. coli 1MI09, 
again yielding three sigmoidal dose-response curves (Fig. 4.5). Magainin 2 N21 at its MIC and 
tetracycline showed no noticable synergism. Magainin 2 N21, at its ICsa, together with 
tetracycline at concentrations below its MIC synergistically inhibited the growth of E. coli 
1M 1 09 by ± 19%. The compounds again showed a decrease in synergism at concentrations of 
tetracycline above its MIC. 
Similar experiments were performed with magainin 2 N I9 and tetracycline on E. coli JMI09. 
Magainin 2 N I9 was used at a concentration double that of the ICsa of magainin 2 N 21 • 
Although magainin 2 N I9 had no antimicrobial activity alone, in conjunction with tetracycline, 
at concentrations below its MIC, the two compounds synergistically inhibited the growth of E. 
coli JM1 09 by ± 9% (Fig. 4.6). Fig. 4.7 compares the synergistic antimicrobial activities of all 
three peptides and tetracycline at concentrations below its MIC. 
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Figure 4.4 Detection of synergism using resistant (A) and non-resistant (B) E. coli. Lines: 
1, tetracycline; 2, tetracycline and magainin 2 at its MIC; and, 3, tetracycline and 
magainin 2 at its IC5o ' 
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Figure 4.5 Detection of synergism using resistant E. coli. Line: 1, tetracycline; 2, 
tetracycline and magainin 2 N2 1 at its MIC; and, 3, tetracycline and magainin 2 
N2 1 at its ICso ' 
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Figure 4.6 Detection of synergism using resistant E. coli. Line: 1, tetracycline; 2, 
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4.4.3 Determination of the combined antimicrobial activity of the 
antimicrobial pep tides and tetracycline on tetracycline resistant E. coli JM109 
To determine the combined antimicrobial effect of the antimicrobial peptides and tetracycline, 
the bacterial inhibition for all data was determined from controls which contained only water. 
In this way the cumulative effect of the peptide and tetracycline could be seen. 
Sigmoidal dose-response curves were again obtained for tetracycline alone, and tetracycline 
with the respective antimicrobial peptides at either their ICso or MIC. In the case of magainin 
2 there was a marked increase in growth inhibition. Magainin 2 at its MIC, together with 
tetracycline at concentrations below its MIC cumulatively inhibited the growth of E. coli by 
±29%. At its ICso, together with tetracycline at concentrations below its MIC, cumulative 
inhibition was ±76% (Fig. 4.8). 
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Figure 4.8 The combined antimicrobial effect of magainin 2 and tetracycline on resistant E. 
coli. Line: 1, tetracycline; 2, tetracycline and magainin 2 at its MIC; and, 3, 
tetracycline and magainin 2 at its ICso ' 
Similar results were obtained with magainin 2 N21• Magainin 2 N21 at its MIC, together with 
tetracycline at concentrations below its MIC inhibited the growth of E. coli by ±15%. 
Magainin 2 N21 at its MIC exhibited no noticable synergism with tetracycline (section 4.4.2), 
the inhibition in this case could therefore be attributed to the peptide. Magainin 2 N21 at its 
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IC so , together with tetracycline at concentrations below its MIC cumulatively inhibited the 
growth of E. coli by ±65% (Fig. 4.9). 
As magainin 2 N I9 exhibited no antimicrobial activity, the synergistic and cumulative effects 
were assumed to be identical. Fig. 4.10 compares the combined antimicrobial activities of all 
three peptides and tetracycline at concentrations below its MIC. 
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Figure 4.9 The combined antimicrobial effect of magainin 2 N 21 and tetracycline on 
resistant E. coli. Line: 1, tetracycline; 2, tetracycline and magainin 2 N21 at its 
MIC; and, 3, tetracycline and magainin 2 N21 at its ICso' 
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Figure 4.10 The combined antimicrobial activity of tetracycline, at concentrations below its 
MIC, and the peptides. Magainin 2 N I9 is not shown as its cumulative effect is 
identical to its synergistic effect which is shown in Fig. 4.6. Duplicate 
experiments were performed. 
4.4.4 Determining the effect of ethanol on the antimicrobial activity of 
magainin 2 
Tetracycline was soluble only in 70% ethanol. Stock solutions contained 5 mg/mL 
tetracycline in 70% ethanol. Concentrations any higher than 5 mg/mL resulted in the 
tetracycline precipitating rapidly out of solution. The dilution of tetracycline with the highest 
concentration (1.6 mg/mL) contained 22% ethanol when diluted with analytical grade water. 
Further doubling dilutions were made, therefore halving the ethanol concentration each time. 
All concentrations of ethanol were tested with the peptide to determine what effect the ethanol 
had on the activity of the peptide as well as bacterial growth. Ethanol had no effect on the 
peptide' s activity or on bacterial growth (Fig. 4.11) 
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Figure 4.11 Concentrations of ethanol showing the effect of the ethanol on bacterial growth 
and the antimicrobial activity of magainin 2 at its IC5o • 
4.5 Conclusions 
The antimicrobial activity decreased rapidly with the removal of amino acids from its N-
terminal. Magainin 2 N21 , which lacked a glycine and isoleucine residue, had approximately 
half the antimicrobial activity of the full length peptide (comparing their IC50 values). 
Magainin 2 N 19, which lacked two glycine residues, an isoleucine, and a lysine residue 
exhibited no discemable antimicrobial activity. In agreement with our results, previous studies 
showed that when magainin 2 is shortened to 19 residues or less from the N-terminal, its 
activity decreases dramatically [8]. This indicates that the amino acid residues making up the 
N-terminal of the peptide are vitally important for the antimicrobial activity of the peptide. 
Magainin 2 exhibited the same degree of activity against both strains of E. coli. Structure 
modelling of the deletion peptides indicated that the omission of the first two amino acid 
residues from the N-terminal of the peptide caused the formation of a cavity in the 
hydrophobic face of the amphipathic a-helix. Omitting two more residues subsequently 
caused the formation of another cavity in the hydrophilic face of the amphipathic a-helix. 
Therefore alterations to the hydrophobic face of the amphipathic a-helix lead to a substantial 
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loss of activity, while alterations to both the hydrophobic and hydrophilic face of the 
amphipathic a-helix lead to complete loss of activity. 
All three peptides exhibited synergism with tetracycline at concentrations below its MIC. The 
degree of synergism correlated with the antimicrobial activity of the peptides. Magainin 2, 
with the highest antimicrobial activity, produced the most synergism in conjunction with 
tetracycline. Magainin 2 N l9 showed no antimicrobial activity alone; however, in conjunction 
with tetracycline at concentrations below its MIC, the two compounds displayed synergism. 
Magainin 2 N 19, although not active enough to lyse the bacterial membrane, therefore still 
succeeds in permeabilising or disrupting the membrane to such an extent that the cell becomes 
more susceptible to tetracycline. From the curves it was clear that no synergism took place at 
tetracycline concentrations above its MIC. Initially it was suspected that at higher tetracycline 
concentrations complexes were being formed between the peptide and tetracycline; however, 
electro spray ionisation mass spectrometry (ESI-MS) revealed no evidence of such complexes 
(data not shown). The ethanol, in which the tetracycline was dissolved, had no effect on the 
activity of the peptide (section 4.4.4). The loss of synergism at tetracycline c~ncentrations 
above its MIC seemed therefore to be caused during the initial interaction of both compounds 
with the bacterial outer membrane. Literature states that magnesium ions (Mg2+) function as 
cationic bridges between adjacent phosphates of lipopolysaccharide molecules in order to 
stabilise the outer membrane [6, 9]. Cationic peptides as well ~s antibiotics are known to 
compete with the Mg2+ cations, thus destroying the LPS cross-bridging and disturbing the 
outer membrane [6]. This also explains why the presence of divalent cations inhibit the 
antimicrobial activity of magainin [6]. We suggest that at higher tetracycline concentrations 
(above its MIC), tetracycline provides stronger competition for the Mg2+ binding sites, 
preventing the peptide from gaining entry into the cell. At lower tetracycline concentrations, 
however, there is a dual competition for the Mg2+ binding sites' and synergism between the 
peptide and tetracycline is observed. 
We have shown magainin 2 to overcome bacterial antibiotic resistance as a result of active 
efflux. On a molecular level, it is unsure how the synergism between tetracycline and 
magainin 2 takes place. In other experiments magainin has been shown to act synergistically 
with certain "standard" antibiotics in the chemotherapy of Gram-negative bacterial infections 
[10]. Synergy between these two antibiotic agents was hypothesised to result from the 
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permeabilising effect of the peptide, which disturbed the integrity of the bacterial membrane 
and facilitated entry of the antibiotic into the bacterial cell [11]. 
These results show that the unique mechanism of action of antimicrobial peptides not only 
allow them to lyse bacterial cells, but also synergistically enhance the antimicrobial activity of 
conventional antibiotics. Finally, the general implications and future prospects of this work 
are summarised in Chapter 5. 
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Chapter 5 
Conclusions 
The aims of this study were first, to synthesise the antimicrobial peptide magainin 2 and two 
N-deletion analogues, second to develop and establish a reliable method to assess the activity 
of antimicrobial peptides against various organisms, and third, to investigate the influence of 
the membrane activity of magainin 2 and two N-deletion analogues on antibiotic resistance. 
The N-terminal deletion analogues were used to deduce the importance of the N-terminal with 
regard to the antimicrobial activity of the peptide. Most of these biologically active peptides 
can be isolated from a variety of sources in nature, this however is an extremely time 
consuming and laborious process [1]. The most effective way of acquiring large amounts of 
pure peptide, and peptide analogues, is through peptide synthesis, and the Fmoc-polyamide 
solid phase peptide synthesis protocol was used to synthesise the peptides used in this study 
(refer to Chapter 2). 
Magainin 2 and two N-terminal deletion analogues were our peptides of choice (Chapter 1). 
The first deletion peptide (magainin 2 N21) was shortened by two amino acids at the 
N-terminal, and the second by four (magainin 2 N 19). Two syntheses were done, the first 
providing insight and experience of the synthesis procedure and purificatio~ of these peptides, 
and the second being an optimisation of the procedure. Through the course of both syntheses 
valuable lessons were learnt about peptide synthesis, as well as the characteristics of magainin 
2. During the first synthesis problems were encountered while coupling Asn22 and Ser23 The 
asparlgme derivative did not couple completely owing to degradation, and the serine 
derivative did not couple sufficiently because it was incompatible with the activation 
procedure used. This highlighted the importance of quality control checks on, and extreme 
purity of, all derivatives and reagents used in peptide synthesis. The unsuccessful coupling of 
asparagine in the first synthesis led to the formation of two deletion peptides, which proved to 
be extremely difficult to remove from the peptide preparations. The consequently large 
number of purification steps also greatly decreased the peptide yields. For the second 
synthesis a serine derivative compatible with the activation procedure and pure asparigine 
were used, both of which coupled successfully. Generally, the second synthesis was highly 
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successful, showing good yields and coupling efficiencies (Table 2.5). The quality of the 
synthesis made the subsequent purification steps relatively simple, and peptides of a high 
purity were obtained, as shown by ESI-MS and analytical HPLC. 
The next section of this study dealt with the development and evaluation of an antimicrobial 
assay (Chapter 3). Assays involving antimicrobial agents are commonly performed using 
agar, agarose or broth media [2]. We developed an assay, termed the micro-gel well diffusion 
assay, by adapting an agarose-based radial diffusion method [3] to perform it in a microtiter 
plate. Agarose was used in place of agar to avoid electrostatic interactions between 
antimicrobial peptides and the polyanionic components of the standard agar [4]. 
Assays, such as the radial diffusion assays, are more commonly used for the detection of 
antimicrobial activity in the discovery stages of antimicrobial peptide research [4]. These 
assays involve the use of an agar or agarose as test matrix, and are exceedingly sensitive and 
require very little test material. In contrast, assays used for routine application in laboratories 
involve the use of a liquid broth medium. These assays are extremely analytical and sensitive, 
and are termed microtiter broth dilution methods [4, 5, 6]. The main reason they are so 
sensitive and analytical is because they can be analysed spectrophotometrically using a 
microtiter plate reader. Initially we made use of an agarose-based radial diffusion method in 
our laboratory [3], which was found not to be sensitive or analytical enough for our 
requirements. It was for these reasons that we made the above mentioned adaptations for the 
development of the micro-gel well diffusion assay. 
In evaluating the micro-gel well diffusion assay it was compared to a radial diffusion assay 
[3] and a microtiter broth dilution method [4, 5, 6]. The micro-gel well diffusion assay 
method compared favourably, being as sensitive as the microtiter broth dilution method and 
approximately twice as sensitive as the radial diffusion assay. The use of light dispersion for 
measuring microbial growth, as opposed to measuring inhibition zones in agarose (as in the 
case of the radial diffusion assay) significantly enhanced sensitivity. Furthermore, agarose as 
a test matrix had numerous advantages over broth: 
• Microbial heterogeneity or contamination can be detected easily by observing the nature 
of bacterial growth on the surface of the agarose; 
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• The medium may be supplemented with whole blood or blood products to permit testing 
of some of the nutritionally fastidious micro-organisms that cannot be tested satisfactorily 
in a clear broth medium; 
• The standard procedure may be modified in a number of ways in order to permit testing of 
a particular type of microorganism or antimicrobial agent, which is quite acceptable as 
long as appropriate controls are included to demonstrate that the modification does not 
affect the end result; 
• Using fixing agents it is possible to halt the experiment at any given time, as well as 
preserve the result for an undetermined period of time. Further treatment with colouring 
agents can also provide an excellent visual record of the result. 
• Finally, with this method we also incorporated and refined a method of data analysis using 
Prism software for the deduction of MIC, IC5o, and MBC values. A statistical analysis of 
the values obtained in each method showed results to be significantly different. This 
indicates that if identical methods are not used, it will not be feasible to compare their 
results. This, however, is an ongoing problem, as there is no single assay compatible with 
all antimicrobial compounds. Therefore for those who require agarose as test matrix, the 
improved sensitivity and analytical capabilities of this agarose-based assay makes the 
micro-gel well diffusion assay comparable to assays used for routine application in 
laboratories. 
The final section of this study, first investigated the influence of N-terminal deletion on the 
antimicrobial activity of magainin 2, and second evaluated the synergistic antimicrobial 
activity of magainin 2 and tetracycline on tetracycline resistant E. coli (resistance incurred 
through active efflux pumps) (Chapter 4). The two N-terminal deletion analogues were also 
used in the synergism studies. 
Initial determinations of the antimicrobial activity of magainin 2 and the N-terminal deletion 
analogues showed that the activity of the peptides decreased substantially with N-terminal 
deletions. The deletion analogue magainin 2 N21 , which lacked a glycine and isoleucine 
residue, had approximately half the antimicrobial activity of the full-length magainin when 
comparing their 1C5o values. Magainin 2 N 19, which lacked two glycine residues, an 
isoleucine, and a lysine residue, exhibited no discernable antimicrobial activity over the 
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concentration range tested. This lack of antimicrobial activity could be attributed to a number 
of factors: first, the shortened peptide chain could result in an inability of the peptide to 
completely span the bacterial membrane, or second, removing amino acids from the 
N-terminal of the peptide could eradicate the peptide's ability to form active peptide 
complexes inside the membrane. Amino acid residues making up the N-terminal of magainin 
2 are therefore vitally important for antimicrobial activity. All,!hree peptides exhibited 
synergism with tetracycline against tetracycline resistant E. coli. The degree of synergism 
correlated with the antimicrobial activity of the peptides. Magainin 2, at and ICso 
concentrations, improved the activity of tetracycline by 12 % and 29% respectively. Magainin 
2 N21 improved the activity of tetracycline by 19 % at its ICso, and showed no effect at its 
MIC. Magainin 2 N 19, although it exhibited no antimicrobial activity, still succeeded in 
improving the activity of tetracycline by approximately 9% when used at an arbitrary 
concentration. 
Synergy between these two antibiotic agents is thought to be the consequence of increased 
membrane permeabilisation by the peptide. By disturbing the integrity of the bacterial 
membrane,' the entry of the antibiotic into the bacterial c~ll was facilitated, therefore reducing 
the effecacy of the efflux-pumps [7]. The decrease in antimicrobial activity of the peptides 
probably resulted in a decreased permeabilisation of the_ bacterial' membrane, causing a 
subsequent reduction in synergistic activity. The exact molecular mechanism of this 
. synergism is not yet known, however it is thought that increased antibiotic entry either occurs 
through the peptide channels, or because of the disruption of the packing of membrane lipids. 
Results obtained with magainin 2 N l9 indicate that synergy with this peptide relied on the 
latter mechanism. From these results it could be deduced that magainin 2 Nl9 interacts with 
the membrane due to its cationic and amphipathic nature, and that this interaction sufficiently 
disrupts the membrane to allow tetracycline entry. 
The common feature of all these observations, was the lack of synergism between the peptides 
and tetracycline at tetracycline concentrations above its MIC. This was found not to be a 
result of peptide-antibiotic complexes or of inhibition of peptide activity by experimental 
reagents. The lack of synergism between the peptides and tetracycline provided further 
information regarding the mode of action of these peptides at the outer membranes of Gram-
negative organisms. Although their mechanism of action has been elucidated to a degree, the 
exact interaction ofthese peptides with bacteria is not yet fully understood [5]. These peptides 
have recently been shown to permeabilise both the inner and outer membranes of 
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Gram-negative bacteria [5]. These experiments could not, however, conclusively state 
whether the ultimate target of the peptide was the inner or outer bacteria membrane [5]. In 
explaining the lack of synergism between the peptides and tetracycline at concentrations 
above its MIC, we proposed a theory based on the ability of both compounds to permeabilise 
the outer bacterial membrane. Magnesium ions (Mg2+) function as cationic bridges between 
adjacent phosphates of lipopolysaccharide molecules in order to stabilise the outer membrane. 
Cationic peptides as well as antibiotics are known to compete with, or for the Mg2+ cations, 
thus destroying the LPS cross-bridging and disturbing the outer membrane. It is suggested 
that at higher tetracycline concentrations (above its MIC), tetracycline provides stronger 
competition for the Mg2+ binding sites, preventing the peptide from having any effect on the 
cell. At lower tetracycline concentrations, however, there is a dual competition for the Mg2+ 
binding sites and synergism between the peptide and tetracycline is observed. Therefore, an 
essential aspect of magainins' mode of action at the outer bacterial membrane of Gram-
negative organIsms is seen to be competition with Mg2+ binding sites to disrupt the 
membrane. 
Therefore, the work presented here not only provided more insight into the mode of action of 
these a-helical antimicrobial peptides, but more importantly also showed them to be an 
effective tool in overcoming the active efflux pumps as a mechanism of bacterial antibiotic 
resistance. 
In conclusion there are numerous future prospects for both the micro-gel well diffusion assay, 
and the synergism studies. As the micro-gel well diffusion assay is specifically designed to 
determine the effect a compound has on microbial growth, it can be used in a diversity of 
fields. We have shown the assay to be compatible with cationic peptides as well as a 
conventional antibiotic, which also displays· the versatility of the assay. As mentioned 
previously, supplementation of the agarose test matrix allows for the use of numerous kinds of 
organisms and antimicrobial compounds, which further enhances the prospects of the assay. 
To further elucidate the mechanism of action of this peptide future experiments would entail 
. the use of a chelating agent, like for instance EDT A, to remove the Mg2+ from binding sites 
and then to note the effect of the peptides and tetracycline. Future studies regarding 
synergistic activity between antimicrobial peptides and antibiotics would most likely entail 
the use of a more clinically relevant organism and antibiotic. Tetracycline and E. coli were 
used in initial studies to develop and optimise a method whereby synergism could be detected. 
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With S. aureus developing such a broad-spectrum of resistance, a clinically relevant organism 
would definitely be methicillin resistant S. aureus. 
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